CA2471063A1 - Novel tfiih subunit - Google Patents
Novel tfiih subunit Download PDFInfo
- Publication number
- CA2471063A1 CA2471063A1 CA 2471063 CA2471063A CA2471063A1 CA 2471063 A1 CA2471063 A1 CA 2471063A1 CA 2471063 CA2471063 CA 2471063 CA 2471063 A CA2471063 A CA 2471063A CA 2471063 A1 CA2471063 A1 CA 2471063A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- tfiih
- nucleotide sequence
- nucleic acid
- ttda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 claims abstract description 192
- 102100032865 General transcription factor IIH subunit 5 Human genes 0.000 claims abstract description 176
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 claims abstract description 112
- 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 claims abstract description 110
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 claims abstract description 109
- 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 52
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 45
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 39
- 241000282414 Homo sapiens Species 0.000 claims abstract description 33
- 230000007812 deficiency Effects 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 238000001415 gene therapy Methods 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 30
- 230000000087 stabilizing effect Effects 0.000 claims description 24
- 230000001737 promoting effect Effects 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 7
- 102100032863 General transcription factor IIH subunit 3 Human genes 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002853 nucleic acid probe Substances 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000013518 transcription Methods 0.000 abstract description 37
- 230000035897 transcription Effects 0.000 abstract description 37
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 241000124008 Mammalia Species 0.000 abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 5
- 206010044628 Trichothiodystrophy Diseases 0.000 abstract description 5
- 208000003059 Trichothiodystrophy Syndromes Diseases 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000003068 molecular probe Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 230000020520 nucleotide-excision repair Effects 0.000 description 65
- 108020004414 DNA Proteins 0.000 description 39
- 108091023040 Transcription factor Proteins 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 23
- 102000040945 Transcription factor Human genes 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 230000033587 transcription-coupled nucleotide-excision repair Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 230000033616 DNA repair Effects 0.000 description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 230000008439 repair process Effects 0.000 description 14
- 230000007547 defect Effects 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 description 12
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 208000010200 Cockayne syndrome Diseases 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 108060004795 Methyltransferase Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102100036883 Cyclin-H Human genes 0.000 description 4
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102000009572 RNA Polymerase II Human genes 0.000 description 4
- 108010009460 RNA Polymerase II Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 108010072268 cyclin-dependent kinase-activating kinase Proteins 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000009395 genetic defect Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 2
- 108010068237 Cyclin H Proteins 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 230000005901 DNA-dependent transcriptional open complex formation Effects 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100032862 General transcription factor IIH subunit 4 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 2
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000017143 RNA Polymerase I Human genes 0.000 description 2
- 108010013845 RNA Polymerase I Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012219 cassette mutagenesis Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000006846 excision repair Effects 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000048295 human GTF2H5 Human genes 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- -1 valise Chemical compound 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 150000005175 2,5-dihydroxybenzoic acids Chemical class 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100493541 Arabidopsis thaliana ATR gene Proteins 0.000 description 1
- CBHVAFXKOYAHOY-NHCYSSNCSA-N Asn-Val-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O CBHVAFXKOYAHOY-NHCYSSNCSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101100226017 Dictyostelium discoideum repD gene Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150105460 ERCC2 gene Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 102100038308 General transcription factor IIH subunit 1 Human genes 0.000 description 1
- INFBPLSHYFALDE-ACZMJKKPSA-N Gln-Asn-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O INFBPLSHYFALDE-ACZMJKKPSA-N 0.000 description 1
- BLOXULLYFRGYKZ-GUBZILKMSA-N Gln-Glu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BLOXULLYFRGYKZ-GUBZILKMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 101100049574 Human herpesvirus 6A (strain Uganda-1102) U5 gene Proteins 0.000 description 1
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 1
- GECLQMBTZCPAFY-PEFMBERDSA-N Ile-Gln-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GECLQMBTZCPAFY-PEFMBERDSA-N 0.000 description 1
- QRTVJGKXFSYJGW-KBIXCLLPSA-N Ile-Glu-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N QRTVJGKXFSYJGW-KBIXCLLPSA-N 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 101150110580 KIN28 gene Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 description 1
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- LMGNWHDWJDIOPK-DKIMLUQUSA-N Lys-Phe-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LMGNWHDWJDIOPK-DKIMLUQUSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MSSJHBAKDDIRMJ-SRVKXCTJSA-N Met-Lys-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MSSJHBAKDDIRMJ-SRVKXCTJSA-N 0.000 description 1
- VWFHWJGVLVZVIS-QXEWZRGKSA-N Met-Val-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O VWFHWJGVLVZVIS-QXEWZRGKSA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100226013 Mus musculus Ercc1 gene Proteins 0.000 description 1
- 101100350989 Mus musculus Paqr7 gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 101150087255 RAD3 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100021991 Solute carrier organic anion transporter family member 6A1 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101001086866 Sus scrofa Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 101150034541 TFB3 gene Proteins 0.000 description 1
- 101150094912 TFB4 gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- YUPVPKZBKCLFLT-QTKMDUPCSA-N Thr-His-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N)O YUPVPKZBKCLFLT-QTKMDUPCSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010083256 Transcription Factor TFIIH Proteins 0.000 description 1
- 102000006288 Transcription Factor TFIIH Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- WFENBJPLZMPVAX-XVKPBYJWSA-N Val-Gly-Glu Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O WFENBJPLZMPVAX-XVKPBYJWSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 108700031763 Xeroderma Pigmentosum Group D Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000007623 carbamidomethylation reaction Methods 0.000 description 1
- 108010089576 carboxy-terminal domain kinase Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150059448 cdk7 gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001876 chaperonelike Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NLJUOWMZPAVXHU-UHFFFAOYSA-N prop-2-enamide;urea Chemical compound NC(N)=O.NC(=O)C=C NLJUOWMZPAVXHU-UHFFFAOYSA-N 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 101150064834 ssl1 gene Proteins 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 101150043651 tfb1 gene Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 108010014677 transcription factor TFIIE Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical class OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention pertains to a nucleic acid sequence encoding a human TFIIH 8kDa subunit and related sequences. The nucleic acids may be used in methods for producing a TFIIH
subunit, as well as in methods for diagnosing or treating transcription and NER deficiencies, in particular in some forms of trichothiodystrophy (TTD). The hTFB5 / TTDA gene and encoded protein may be used for therapy or genetherapy products, aimed at treating congenital NER
disorders and may also be used in methods of diagnosis of disorders in basal transcription, NER
and TCR activity in mammals, using molecular probes or antibodies specific for TTDA.
subunit, as well as in methods for diagnosing or treating transcription and NER deficiencies, in particular in some forms of trichothiodystrophy (TTD). The hTFB5 / TTDA gene and encoded protein may be used for therapy or genetherapy products, aimed at treating congenital NER
disorders and may also be used in methods of diagnosis of disorders in basal transcription, NER
and TCR activity in mammals, using molecular probes or antibodies specific for TTDA.
Description
Novel TFIIH subunit Field of the invention The present invention relates to the fields of cell biology and medicine, in particular to gene transcription and DNA repair systems, more in particular to the detection and treatment of defects in basal and activated transcription, nucleotide excision repair (NER) and transcription coupled repair systems in mammals and in mammalian cells.
Background of the invention TFIIH is a multicomponent basal transcription factor complex. Transcription factor II H
interacts with a variety of factors during transcription, including nuclear receptors, tissue-specific transcription factors, chromatin remodeling complexes and RNA, suggesting that, in addition to its essential role in transcription initiation for RNA polymerases I and II, it also participates as a regulatory factor. To date, at least nine subunits have been identified within the TFIIH
holoenzyme complex in mammals. Various enzymatic activities, including DNA
repair, helicase, and cyclin dependent kinase activities, have been reported. The nine known subunits of the TFIIH complex are summarized in table 2.
TFIIH is involved in transcription from RNA polymerase I (ribosomal RNA's) and RNA
polymerase II (messenger RNA) transcription. TFIIH is essential for promoter melting, the separation of the DNA strands that make up the double helix, and/or for promoter clearance (i.e.
for pol II to break free of the initiation complex into elongation mode).
Surprisingly, TFIIH also is essential for the core reaction of Nucleotide Excision Repair (NER) of damaged DNA
templates. In addition, TFIIH appears to play an important role in a subpathway of NER, the preferential repair of actively transcribed regions on the DNA; the so-called transcription coupled DNA repair (TCR) process which is restricted to the repair of NER-type of lesions but also includes the TCR of oxidative DNA lesions.
The XPB, XPD, p62, p52, p44, and p34 subunits are thought to constitute the "core" of the TFIIH transcription machinery. The two largest TFIIH subunits, XPB and XPD, are ATP-dependent helicases of opposite polarity, crucial for promoter melting. Two of the smaller subunits have possible zinc finger domains. Although the p44 and p34 subunits have no defined enzymatic activity, their zinc finger structures suggest that they may be DNA-binding proteins that might mediate interactions with soluble transcription factors. TFIIH
appears to be dependent A9cC:artlm Tetrault LLl' TDO-RED #823GSJ0 v. i upon TFIIE for incorporation into the pre-initiation complex, the assembly of basal transcription factors and the polymerase on promoters of transcribed genes. The Cdk-activating kinase (CAK) subcomplex, comprising subunits Cdk7, cyclin H, and MAT1, phosphorylate several cyclin-dependent kinases (Cdks). The associated kinase activity (also referred to as TFIIK) can phosphorylate the C-terminal domain of the RNA pol II largest subunit. This phosphorylation at serines and threonines is essential for DNA transcription, i.e. for elongation of the RNA chain.
Besides the central role TFIIH plays in RNA polymerase I and II transcription, it is also involved in nucleotide excision repair (NER) and transcription-coupled repair (TCR) (Egly, J.M.
FEBS Lett. 498, 124-128 (2001 ). NER removes a wide range of DNA helix-distorting injuries, including ultraviolet light (LTV)-induced lesions (Hoeijmakers, J.H., Nature 411, 366-374, 2001).
TCR is a repair pathway that eliminates both classical NER lesions and oxidative DNA injuries from the transcribed strand (de Boer, J. et al., Science 296, 1276-1279, 2002 and Le Page, F. et al., Cell 101, 159-171, 2000).
Several hereditary mutations in repair/transcription factor TFIIH subunits are associated with three photo-hypersensitive syndromes in man: 1 ) xeroderma pigmentosum (XP), 2) XP
combined Cockayne syndrome (CS), a neuro-developmental disorder, and 3) the CS-like brittle hair disease trichothiodystrohpy (TTD)( Lehmann, A.R., Genes Dev 15, 15-23, 2001 and Bootsma et al., in Nucleotide Excision Repair Syndromes: Xeroderma Pigmentosum, Cockayne Syndromes. And Trichothiodystrophy., 245-274, New york, 1998 ), summarized in table 1.
Photosensitive features of XP patients are mainly caused by defective NER, whereas the CS and TTD features are attributed to an affected TCR and transcription function, which result in premature or enhanced ageing symptoms or phenotypes.
Trichothiodystrophy (TTD) is a rare autosomal recessive disorder characterized by sulfur-deficient brittle hair and ichthyosis (Itin et al. 2001). Hair shafts split longitudinally into small fibers, and this brittleness is associated with levels of cysteine/cystine in hair proteins that are 15 to 50% of those in normal individuals. The hair has characteristic "tiger-tail" banding visible under polarized light. The patients often have an unusual facial appearance, with protruding ears and a receding chin. Mental abilities range from low normal to severe retardation. Several categories of the disease can be recognized on the basis of cellular responses to LJV damage and the affected gene.
A4cCar~th~: Tetrnult LLP TDO-RED #823GSI0 v. l Evidence from complementation tests by cell fusion experiments identified that the TTD
phenotype can be caused by mutations in at least 2 separate genes: ERCC2/XPD
and ERCC3/XPB, which encode the 2 helicase subunits of transcription/repair factor TFIIH
(Broughton, B.C. et al., Hum. Mol. Genet. 10, 2539-2547, 2001, Botta, E. et al., Am. J. Hum.
Genet. 63, 1036-1048, 1998, Weeda, G. et al. Am. J. Hum. Genet. 60, 320-329, 1997, Graham, J.M., Jr. et al. Am. J. Hum. Genet. 69, 291-300, 2001). Besides XP groups B
and D, an exceptional trichothiodystrophy complementation group designated TTD-A was identified by Stefanini et al., (Am J Hum Genet 53, 817-21, 1993). The third, yet unidentified gene causing photosensitive TTD (Vermeulen, W. et al., Cold Spring Harb. Symp. Quant. Biol.
59, 317-329, 1994), designated TTDA also appeared associated with TFIIH (Vermeulen, W. et al., Nat. Genet.
26, 307-13, 2000). Table 1 summarizes the clinical and cellular features of all known TTD-A
cases, including two new group A families. Cells from TTD-A patients are only mildly UV-sensitive despite the low UV-induced DNA repair synthesis (Unscheduled DNA
Synthesis (UDS), non-replicative DNA synthesis which takes place throughout the entire cell cycle, including Gi-, S- , and G2-phase of the cell cycle). Remarkably, in the third form of DNA-repair deficient TTD complementation group A, none of the nine TFIIH encoding subunits carried mutations; instead the steady-state level of the entire complex was severely reduced. A
comprehensive and frequently updated list of 363 TTD, CS and XP mutations in humans can be found on www.xpmutations.or~.
Previously, the inventors found that highly purified TFIIH corrected the NER
defect of TTD-A cells, although none of the nine TFIIH genes were mutated in TTD-A.
Moreover, TFIIH
isolated from TTD-A cells displayed normal in vitro enzymatic activities and transiently restored the NER defect in TTD-A cells after microinjection, suggesting that TFIIH was qualitatively not or only mildly affected.
The cum-ent invention provides for nucleic acids that encode a novel 8 kDa subunit of TFIIH and that may be used in the diagnosis and therapy of the nucleotide excision repair (NER) deficiencies, transcription coupled repair (TCR) deficiencies and DNA
transcription deficiencies, in particular trichothiodistrophy.
~4c('artho Tewnull LLI' TDO-RED #82365/0 n. l Detailed description of the invention Here we describe the identification of the human TFBS ortholog and its association with human TFIIH. Recently, a novel, tenth TFIIH subunit (TFBS), was identified in yeast.
Within a quantitative proteomic screening of promoter-associated RNA
polymerase II
preinitiation complexes from yeast nuclear extracts, a novel, very small protein of 72 amino acids (~ 8 kDa) was identified and shown to be a core component of yeast TFIIH, designated TFBS (Ranish, J.A. et al., Nat. Genet. 2004). This protein was overlooked in previous analyses of TFIIH due to its exceptionally small size.
Data base screening identified several orthologs of TFBS (Figure 5), including a presumed human homologue. The human TFBS gene codes for a 71 amino acid polypeptide with a predicted molecular weight of 8 kDa (referred to as p8). TFBS appeared highly conserved, with a sequence identity of 25 % and 56 % similarity between human and yeast. The strong evolutionary conservation of each TFIIH subunit (Table 2 and figure 5) in combination with the overall structural homology of the complex (Schultz, P. et al., Cell 102, 599-607, 2000 and Chang, W.H. & Kornberg, R.D., Cell 102, 609-613, 2000), prompted us to investigate whether human TFBS is also part of mammalian TFIIH and whether it is the enigmatic TTDA
factor.
Microinjection of hTFBS cDNA corrected the DNA repair defect of TTD-A cells and three functional inactivating mutations were identified in three unrelated TTD-A
families. This TTDA
gene product was shown to play a role in regulating the level of TFIIH and significantly stabilizes the TFIIH complex in vivo. The identification of a new evolutionarily conserved subunit of TFIIH implicated in TTD-A, provides important solutions for diagnosing and treating TFIIH dysfunction in transcription, DNA repair systems, in particular NER and TCR systems and human diseases associated with NER and TCR dysfunction.
In a first aspect the invention relates to a nucleic acid molecule comprising a sequence encoding a polypeptide with TFIIH stabilizing activity and/or NER promoting activity. The nucleic acid molecule is preferably selected from the group consisting of: (a) nucleic acid molecules encoding a polypeptide comprising an amino acid sequence having at least 50, 60, 70, 80, 90, 95, 98 or 99% identity with the amino acid sequence of SEQ ID N0:2 ;
(b) nucleic acid molecules the complementary strand of which hybridises to a nucleic acid molecule having a McCurth~: Tetrault LLI' TDO-RED #8236510 0. l nucleotide sequence as depicted in SEQ ID N0:2 ; and, (c) nucleic acid molecules the sequence of which differs from the nucleic acid molecule of (a) or (b) due to the degeneracy of the genetic code.
A polypeptide with TFIIH stabilizing and/or NER promoting activity is herein understood to mean a polypeptide that is capable of stabilizing TFIIH as determined in a functional assay, preferably the assay herein provided in example 4, and/or active in NER
promoting activity as determined by a functional NER assay and/or an assay specific for the TCR
subpathway, preferably the assay provided in example 3. A further functional assay for TFIIH stabilizing and/or NER promoting activity is provided by complementation of TTD-A cells (i.e. TTD cells that belong to the TTD-A complementation group). A polypeptide with TFIIH
stabilizing and/or NER promoting is herein understood to be capable of correcting the DNA repair defect of TTD-A cells, e.g. by microinjection of the polypeptide or a nucleic acid construct capable of expressing the polypeptide.
"Sequence identity" is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988;
Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heine, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M
Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J.
Applied Math., 48:1073 (1988).
Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available Mc(.arthn Turm~h LLI' TDO-RED #8236510 0. l computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, BLASTP, BLASTN, and FASTA
(Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990). The BLAST X program is publicly available from NCBI
and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894;
Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.
Preferred parameters ,for polypeptide sequence comparison include the following:
Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix:
BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-( 1992); Gap Penalty: 12; and Gap Length Penalty: 4. A program useful with these parameters is publicly available as the "Ogap" program from Genetics Computer Group, located in Madison, WI. The aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
Preferred parameters for nucleic acid comparison include the following:
Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: matches=+10, mismatch=0;
Gap Penalty: 50; Gap Length Penalty: 3. Available as the Gap program from Genetics Computer Group, located in Madison, Wisconsin. Given above are the default parameters for nucleic acid comparisons.
Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called "conservative" amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valise, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; a group of amino acids having acidic side chains is aspartic acid and glutamic acid and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
Preferred conservative amino acids substitution groups are: valise-leucine-isoleucine, McC artho Tetrault LLl' TDO-RED #d?3G5l0 v. !
phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gln or his; Asp to glu; Cys to ser or ala; Gln to asn; Glu to asp; Gly to pro; His to asn or gln;
Ile to leu or val; Leu to ile or val; Lys to arg; gln or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser;
Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
Nucleic acid sequences encoding polypeptides having TFIIH stabilizing activity and/or NER promoting activity may also be defined by their capability to hybridise with the (complementary strand of) the nucleotide sequence of SEQ ID NO: 2, preferably under moderate, or more preferably under stringent hybridisation conditions.
Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0,1 M salt, or less, preferably 0,2 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having about 90% or more sequence identity.
Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least SO nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M
salt, preferably 6 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is perforned for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence A~IcCar~h~= Tetrnul~ LLP TDO-RED #8236510 n. I
_g_ identity. The person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 99%.
The nucleic acid molecules of the invention preferably encode a polypeptide with TFIIH
stabilizing and/or NER promoting activity that is a mammalian, preferably a human TTDA
protein or a murine TTDA protein.
In a further aspect, the invention relates to a nucleic acid probe comprising a part of a nucleotide sequence that has at least 90% with a nucleotide sequence as depicted in SEQ ID NO:
2, or its complement sequence. Preferably, the probe comprises a part of a nucleotide sequence that has at least 90% with a nucleotide sequence as depicted in SEQ ID NO: 2 from positions 1 to 331 more preferably from positions 60 to 275. Nucleic acid probes are used to analyse nucleic acids encoding the polypeptide having TFIIH stabilizing and NER promoting activity. Such analysis may include the analysis of the genotype of a subject with respect to sequence encoding TTDA, e.g. the presence or absence of specific mutations or alleles, or may involve analysis of the expression of nucleic acids encoding TTDA. The subject may be a mammal and preferably is a human. Such analyses may be performed for diagnostic purposes (see below).
Nucleic acid probes thus include poly- and oligonucleotides for use as hybridisation probes, as primers for sequencing or amplification and for use in techniques such as Oligonucleotide Ligation (-Amplification) assays (see e.g. US 4,988,617; US 5,876,924; WO 96/15271; and WO 97/45559) or Single-Strand Conformational Polymorphism assays (see e.g. Orita et al., 1989, Genomics 5:
874-879). For further nucleic acid analysis techniques reference is made to Sambrook and Russell (2001, Molecular Cloning: A Laboratory Manual, 3~d edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY). A preferred nucleic acid probe is a probe that comprises at least 10, 12, 14, 16 or 20 contiguous nucleotides of a nucleotide sequence that has at least 70, 80 or 90% identity with a nucleotide sequence as depicted in SEQ
ID NO: 2, which spans the entire coding sequence of the human hTFBS / TTDA gene. Probes derived from SEQ
ID NO: 2 or the genomic TTDA locus, SEQ ID. NO. 3, 4 and 5, may thus be used to analyse both exonic and intronic sequences as well as non-coding sequence up- or downstream from the transcription unit that may be involved in the regulations of expression of the TTDA / hTFBS
gene. A probe according to the current invention comprising a stretch of nucleic acids may be A~IcC'crrlhr Tewcrult LLT' TDO-RED #82365/0 n. I
advantageously physically linked to a solid support, such as, but not limited to, a DNA (micro-) array.
In another aspect the invention relates to a vector comprising a nucleic acid molecule or probe as defined above. Preferably the vector is a replicative vector comprising an origin of replication (or autonomously replication sequence) that ensures multiplication of the vector in a suitable host for the vector. Alternatively the vector is capable of integrating into the host cell's genome, e.g. through homologous recombination, random integration or otherwise.
A particularly preferred vector is an expression vector that wherein a nucleotide sequence encoding a polypeptide with TFIIH stabilizing and/or NER promoting activity as defined above, is operably linked to a promoter capable of directing expression of the coding sequence in a host cell for the vector.
As used herein, the term "promoter" refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A "constitutive" promoter is a promoter that is active under most physiological and developmental conditions. An "inducible" promoter is a promoter that is regulated depending on physiological or developmental conditions. A "tissue specific" promoter is only active in specific types of differentiated cells/tissues.
Expression vectors allow the polypeptides with TFIIH stabilizing and/or NER
promoting activity of the present invention to be prepared using recombinant techniques in which a nucleotide sequence encoding the polypeptide of interest is expressed in suitable cells, e.g.
cultured cells or cells of a multicellular organism, such as described in Ausubel ed., "Current Protocols in Molecular Biology", Greene Publishing and Wiley-Interscience, New York (2003) and in Sambrook and Russell (2001, supra); both of which are incorporated herein by reference in their entirety. Also see, Kunkel (1985) Proc. Natl. Acad. Sci. 82:488 (describing site directed McC'nrth> Teu-ault LLI' TDO-RED #8236510 v. l mutagenesis) and Roberts et al. (1987) Nature 328:731-734 or Wells, J.A., et al. (1985) Gene 34:315 (describing cassette mutagenesis).
Typically, nucleic acids encoding the desired polypeptides are used in expression vectors.
The phrase "expression vector" generally refers to nucleotide sequences that are capable of affecting expression of a gene in hosts compatible with such sequences. These expression vectors typically include at least suitable promoter sequences and optionally, transcription termination signals. Additional factors necessary or helpful in effecting expression can also be used as described herein. DNA encoding a polypeptide is incorporated into DNA
constructs capable of introduction into and expression in an in vitro cell culture. Specifically, DNA constructs are suitable for replication in a prokaryotic host, such as bacteria, e.g., E.
coli, or can be introduced into a cultured mammalian, plant, insect, e.g., Sf~, yeast, fungi or other eukaryotic cell lines.
DNA constructs prepared for introduction into a particular host typically include a replication system recognised by the host, the intended DNA segment encoding the desired polypeptide, and transcriptional and translational initiation and termination regulatory sequences operably linked to the polypeptide-encoding segment. A DNA segment is "operably linked"
when it is placed into a functional relationship with another DNA segment. For example, a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence. DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide. Generally, DNA
sequences that are operably linked are contiguous, and, in the case of a signal sequence, both contiguous and in reading phase. However, enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
The selection of an appropriate promoter sequence generally depends upon the host cell selected for the expression of the DNA segment. Examples of suitable promoter sequences include prokaryotic, and eukaryotic promoters well known in the art (see, e.g.
Sambrook and Russell, 2001, supra). The transcriptional regulatory sequences typically include a heterologous enhancer or promoter that is recognised by the host. The selection of an appropriate promoter depends upon the host, but promoters such as the trp, lac and phage promoters, tRNA
promoters and glycolytic enzyme promoters are known and available (see, e.g. Sambrook and Russell, 2001, McCartht: Terraol~ LLP TDO-RED #823GSI0 v. l supra). Expression vectors include the replication system and transcriptional and translational regulatory sequences together with the insertion site for the polypeptide encoding segment can be employed. Examples of workable combinations of cell lines and expression vectors are described in Sambrook and Russell (2001, supra) and in Metzger et al. (1988) Nature 334: 31-36.
For example, suitable expression vectors can be expressed in, yeast, e.g.
S.cerevisiae, insect cells, e.g., Sf9 cells, mammalian cells, e.g., CHO cells and bacterial cells, e.g., E. coli.
In vitro mutagenesis and expression of mutant proteins are described generally in Ausubel et al. (2003, supra) and in Sambrook and Russell (2001, supra). Also see, Kunkel (1985, supra;
describing site directed mutagenesis) and Roberts et al. (1987, supra;
describing cassette mutagenesis).
Another method for preparing polypeptides is to employ an in vitro transcription/translation system. DNA encoding a polypeptide is cloned into an expression vector as described supra. The expression vector is then transcribed and translated in vitro. The translation product can be used directly or first purified. Polypeptides resulting from in vitro translation typically do not contain the post-translation modifications present on polypeptides synthesised in vivo, although due to the inherent presence of microsomes some post-translational modification may occur. Methods for synthesis of polypeptides by in vitro translation are described by, for example, Berger & Kimmel, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques, Academic Press, Inc., San Diego, CA, 1987.
In a further aspect the invention thus relates to a host comprising a vector as defined above.
The host cells may be prokaryotic or eukarotic host cells as indicated above.
The host cell may be a host cell that is suitable for culture in liquid or on solid media.
Alternatively, the host cell is a cell that is part of a multicellular organism such as a transgenic plant or animal, preferably a non-human animal.
A further aspect the invention relates to a method for producing a polypeptide with TFIIH
stabilizing activity and/or NER promoting activity. The method comprises the step of culturing a host cell as defined above under conditions conducive to the expression of the polypeptide.
Optionally the method may comprise recovery the polypeptide. The polypeptide may e.g. be recovered from the culture medium by standard protein purification techniques, including a variety of chromatography methods known in the art per se.
McCczrtho Tetranlt LLP TDO-RED #82365/0 v. 1 Another aspect of the invention relates to a transgenic animal comprising in its somatic and germ cells a vector as defined above. The transgenic animal preferably is a non-human animal.
Methods for generating transgenic animals are e.g. described in WO 01157079 and in the references cited therein. Such transgenic animals may be used in a method for producing a polypeptide with TFIIH stabilizing activity and or NER promoting activity, the method comprising the step of recovering a body fluid or tissue from a transgenic animal comprising the vector or a female descendant thereof, wherein the body fluid contains the polypeptide, and, optionally recovery of the polypeptide from the body fluid. Such methods are also described in WO 01/57079 and in the references cited therein. The body fluid containing the polypeptide preferably is blood or more preferably milk. In another embodiment the transgenic animal may be a knock out animal, wherein the endogenous TTDA alleles) have been replaced with a dysfunctional or mutated alleles) via homologous recombination techniques known in the art.
For instance the TTDA reading frame may be deleted or disrupted by insertion of a sequence and/or fused to selectable marker Neomycin R(esistance), Hygromycin R, DHFR, puromycin R, HSVtk or reporter genes such as luciferase. Also bi-cistronic messengers of TTDA and a marker allele maybe constructed using an IRES sequence. In other embodiments conditional knock outs or knock in animals may be constructed using the Cre-Lox or Frt/Flp recombinase systems known in the art. In yet another embodiment the transgenic animal may be a knock-in animal in which one or both copies of the TTDA alleles are replaced by sequences coding for tagged forms of TTDA. Various tags that are suitable for fusion with the TTDA reading frame, including e.g.
fluorescent proteins such GFP and variants thereof, as well as affinity tags, are well known in the art (see below). In yet another embodiment RNA interference (RNAi) strategies known in the art and RNAi molecules may be applied to inactivate expression of TTDA locally or systemically in a mammal or in cells.
A further aspect of the invention relates to a polypeptide polypeptide with TFIIH
stabilizing activity and or NER promoting activity and comprising an amino acid sequence having at least 80, 90, 95, 98 or 99% identity with the amino acid sequence of SEQ ID NO: 1.
The polypeptide is further preferably as described above. Included within the scope of the invention are mutant polypeptides having TFIIH stabilizing activity and or NER
promoting activity with e.g. altered specificity or additional features, such as but not limited to fusions to McC.'czrtha= Tetrnult LLP TDO-RED #823GSI0 v. I
molecular tags that may be used for (but not limited to) purification/isolation, identification, visualizatioWlocalization o'r immunization purposes. The amino acid sequence of SEQ ID No. 1 may be fused to an HA, FLAG, myc, multiple-His, double HA, tubulin, GST, protein A, MBP, biotin or any other tag known in the art. Also fluorescent tags may be advantageously applied, S such as GFP, EGFP, eCFP, eYFP, dsRed, RFP, GFP2, FLASH, SNAP and other fluorescent protein tags, or tags that bind specifically to fluorescent small molecular entities, quantum dots or any molecules known in the art. Based on the specific activities of TTDA in stabilizing TFIIH, promoting NER and TCR and promoting DNA transcription, the skilled person will know how to modify essential amino acids by minor amino acid substitutions and or deletions, insertion and fusions to alter its cellular activities, increase or decrease affinities for its natural or artificial binding partners in the TFIIH complex, increase the half life of the protein, fuse it to tags or fluorescent reporters as mentioned above. The tertiary structure of a TTDA
protein based on the enzyme depicted in SEQ ID NO: 1 may be altered applying the same principle as above to adapt the structure to modulate the structure of the interaction sites of the protein and subsequently assay the mutant for its TFIIH stabilizing activity and/or its promoting activity for NER, TCR
and DNA transcription.
Another aspect of the invention relates to an antibody or antibody-fragment that specifically binds to a polypeptide with TFIIH stabilizing and/or NER
promoting activity as defined above. Methods for generating monoclonal or polyclonal antibodies or antibody-fragments that specifically binds to a given polypeptide are described in e.g.
Harlow and Lane ( 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) and WO 91/19818; WO 91/18989; WO 92/01047; WO 92/06204; WO
92/18619;
US 6,420,113 and W002/085944 and references cited therein, and comprise VL, VH, scFv, Fab, Fab2 fragments as well as camelid single chain antibodies or antibodies or antibody-fragments from phage-display libraries. The term "specific binding," as used herein, includes both low and high affinity specific binding. Specific binding can be exhibited, e.g., by a low affinity antibody or antibody-fragment having a Kd of at least about 10-4 M. Specific binding also can be exhibited by a high affinity antibody or antibody-fragment, for example, an antibody or antibody-fragment having a Kd of at least about of 10-7 M, at least about 10-8 M, at least about 10-9 M, at least about 10-10 M, or can have a Kd of at least about 10-11 M or 10-12 M or A4cC'artho Tetrnult LLP TDO-RED #8236,110 v. I
greater. Antibodies may be raised in any mammal, and antibodies may preferably be humanized or deimmunized.
Another aspect of the invention relates to microarrays (or other high throughput screening devices) comprising the nucleic acids or polypeptides as defined above. A
microarray is a solid support or carrier containing one or more immobilised nucleic acid or polypeptide fragments for analysing nucleic acid or amino acid sequences or mixtures thereof (see e.g.
Background of the invention TFIIH is a multicomponent basal transcription factor complex. Transcription factor II H
interacts with a variety of factors during transcription, including nuclear receptors, tissue-specific transcription factors, chromatin remodeling complexes and RNA, suggesting that, in addition to its essential role in transcription initiation for RNA polymerases I and II, it also participates as a regulatory factor. To date, at least nine subunits have been identified within the TFIIH
holoenzyme complex in mammals. Various enzymatic activities, including DNA
repair, helicase, and cyclin dependent kinase activities, have been reported. The nine known subunits of the TFIIH complex are summarized in table 2.
TFIIH is involved in transcription from RNA polymerase I (ribosomal RNA's) and RNA
polymerase II (messenger RNA) transcription. TFIIH is essential for promoter melting, the separation of the DNA strands that make up the double helix, and/or for promoter clearance (i.e.
for pol II to break free of the initiation complex into elongation mode).
Surprisingly, TFIIH also is essential for the core reaction of Nucleotide Excision Repair (NER) of damaged DNA
templates. In addition, TFIIH appears to play an important role in a subpathway of NER, the preferential repair of actively transcribed regions on the DNA; the so-called transcription coupled DNA repair (TCR) process which is restricted to the repair of NER-type of lesions but also includes the TCR of oxidative DNA lesions.
The XPB, XPD, p62, p52, p44, and p34 subunits are thought to constitute the "core" of the TFIIH transcription machinery. The two largest TFIIH subunits, XPB and XPD, are ATP-dependent helicases of opposite polarity, crucial for promoter melting. Two of the smaller subunits have possible zinc finger domains. Although the p44 and p34 subunits have no defined enzymatic activity, their zinc finger structures suggest that they may be DNA-binding proteins that might mediate interactions with soluble transcription factors. TFIIH
appears to be dependent A9cC:artlm Tetrault LLl' TDO-RED #823GSJ0 v. i upon TFIIE for incorporation into the pre-initiation complex, the assembly of basal transcription factors and the polymerase on promoters of transcribed genes. The Cdk-activating kinase (CAK) subcomplex, comprising subunits Cdk7, cyclin H, and MAT1, phosphorylate several cyclin-dependent kinases (Cdks). The associated kinase activity (also referred to as TFIIK) can phosphorylate the C-terminal domain of the RNA pol II largest subunit. This phosphorylation at serines and threonines is essential for DNA transcription, i.e. for elongation of the RNA chain.
Besides the central role TFIIH plays in RNA polymerase I and II transcription, it is also involved in nucleotide excision repair (NER) and transcription-coupled repair (TCR) (Egly, J.M.
FEBS Lett. 498, 124-128 (2001 ). NER removes a wide range of DNA helix-distorting injuries, including ultraviolet light (LTV)-induced lesions (Hoeijmakers, J.H., Nature 411, 366-374, 2001).
TCR is a repair pathway that eliminates both classical NER lesions and oxidative DNA injuries from the transcribed strand (de Boer, J. et al., Science 296, 1276-1279, 2002 and Le Page, F. et al., Cell 101, 159-171, 2000).
Several hereditary mutations in repair/transcription factor TFIIH subunits are associated with three photo-hypersensitive syndromes in man: 1 ) xeroderma pigmentosum (XP), 2) XP
combined Cockayne syndrome (CS), a neuro-developmental disorder, and 3) the CS-like brittle hair disease trichothiodystrohpy (TTD)( Lehmann, A.R., Genes Dev 15, 15-23, 2001 and Bootsma et al., in Nucleotide Excision Repair Syndromes: Xeroderma Pigmentosum, Cockayne Syndromes. And Trichothiodystrophy., 245-274, New york, 1998 ), summarized in table 1.
Photosensitive features of XP patients are mainly caused by defective NER, whereas the CS and TTD features are attributed to an affected TCR and transcription function, which result in premature or enhanced ageing symptoms or phenotypes.
Trichothiodystrophy (TTD) is a rare autosomal recessive disorder characterized by sulfur-deficient brittle hair and ichthyosis (Itin et al. 2001). Hair shafts split longitudinally into small fibers, and this brittleness is associated with levels of cysteine/cystine in hair proteins that are 15 to 50% of those in normal individuals. The hair has characteristic "tiger-tail" banding visible under polarized light. The patients often have an unusual facial appearance, with protruding ears and a receding chin. Mental abilities range from low normal to severe retardation. Several categories of the disease can be recognized on the basis of cellular responses to LJV damage and the affected gene.
A4cCar~th~: Tetrnult LLP TDO-RED #823GSI0 v. l Evidence from complementation tests by cell fusion experiments identified that the TTD
phenotype can be caused by mutations in at least 2 separate genes: ERCC2/XPD
and ERCC3/XPB, which encode the 2 helicase subunits of transcription/repair factor TFIIH
(Broughton, B.C. et al., Hum. Mol. Genet. 10, 2539-2547, 2001, Botta, E. et al., Am. J. Hum.
Genet. 63, 1036-1048, 1998, Weeda, G. et al. Am. J. Hum. Genet. 60, 320-329, 1997, Graham, J.M., Jr. et al. Am. J. Hum. Genet. 69, 291-300, 2001). Besides XP groups B
and D, an exceptional trichothiodystrophy complementation group designated TTD-A was identified by Stefanini et al., (Am J Hum Genet 53, 817-21, 1993). The third, yet unidentified gene causing photosensitive TTD (Vermeulen, W. et al., Cold Spring Harb. Symp. Quant. Biol.
59, 317-329, 1994), designated TTDA also appeared associated with TFIIH (Vermeulen, W. et al., Nat. Genet.
26, 307-13, 2000). Table 1 summarizes the clinical and cellular features of all known TTD-A
cases, including two new group A families. Cells from TTD-A patients are only mildly UV-sensitive despite the low UV-induced DNA repair synthesis (Unscheduled DNA
Synthesis (UDS), non-replicative DNA synthesis which takes place throughout the entire cell cycle, including Gi-, S- , and G2-phase of the cell cycle). Remarkably, in the third form of DNA-repair deficient TTD complementation group A, none of the nine TFIIH encoding subunits carried mutations; instead the steady-state level of the entire complex was severely reduced. A
comprehensive and frequently updated list of 363 TTD, CS and XP mutations in humans can be found on www.xpmutations.or~.
Previously, the inventors found that highly purified TFIIH corrected the NER
defect of TTD-A cells, although none of the nine TFIIH genes were mutated in TTD-A.
Moreover, TFIIH
isolated from TTD-A cells displayed normal in vitro enzymatic activities and transiently restored the NER defect in TTD-A cells after microinjection, suggesting that TFIIH was qualitatively not or only mildly affected.
The cum-ent invention provides for nucleic acids that encode a novel 8 kDa subunit of TFIIH and that may be used in the diagnosis and therapy of the nucleotide excision repair (NER) deficiencies, transcription coupled repair (TCR) deficiencies and DNA
transcription deficiencies, in particular trichothiodistrophy.
~4c('artho Tewnull LLI' TDO-RED #82365/0 n. l Detailed description of the invention Here we describe the identification of the human TFBS ortholog and its association with human TFIIH. Recently, a novel, tenth TFIIH subunit (TFBS), was identified in yeast.
Within a quantitative proteomic screening of promoter-associated RNA
polymerase II
preinitiation complexes from yeast nuclear extracts, a novel, very small protein of 72 amino acids (~ 8 kDa) was identified and shown to be a core component of yeast TFIIH, designated TFBS (Ranish, J.A. et al., Nat. Genet. 2004). This protein was overlooked in previous analyses of TFIIH due to its exceptionally small size.
Data base screening identified several orthologs of TFBS (Figure 5), including a presumed human homologue. The human TFBS gene codes for a 71 amino acid polypeptide with a predicted molecular weight of 8 kDa (referred to as p8). TFBS appeared highly conserved, with a sequence identity of 25 % and 56 % similarity between human and yeast. The strong evolutionary conservation of each TFIIH subunit (Table 2 and figure 5) in combination with the overall structural homology of the complex (Schultz, P. et al., Cell 102, 599-607, 2000 and Chang, W.H. & Kornberg, R.D., Cell 102, 609-613, 2000), prompted us to investigate whether human TFBS is also part of mammalian TFIIH and whether it is the enigmatic TTDA
factor.
Microinjection of hTFBS cDNA corrected the DNA repair defect of TTD-A cells and three functional inactivating mutations were identified in three unrelated TTD-A
families. This TTDA
gene product was shown to play a role in regulating the level of TFIIH and significantly stabilizes the TFIIH complex in vivo. The identification of a new evolutionarily conserved subunit of TFIIH implicated in TTD-A, provides important solutions for diagnosing and treating TFIIH dysfunction in transcription, DNA repair systems, in particular NER and TCR systems and human diseases associated with NER and TCR dysfunction.
In a first aspect the invention relates to a nucleic acid molecule comprising a sequence encoding a polypeptide with TFIIH stabilizing activity and/or NER promoting activity. The nucleic acid molecule is preferably selected from the group consisting of: (a) nucleic acid molecules encoding a polypeptide comprising an amino acid sequence having at least 50, 60, 70, 80, 90, 95, 98 or 99% identity with the amino acid sequence of SEQ ID N0:2 ;
(b) nucleic acid molecules the complementary strand of which hybridises to a nucleic acid molecule having a McCurth~: Tetrault LLI' TDO-RED #8236510 0. l nucleotide sequence as depicted in SEQ ID N0:2 ; and, (c) nucleic acid molecules the sequence of which differs from the nucleic acid molecule of (a) or (b) due to the degeneracy of the genetic code.
A polypeptide with TFIIH stabilizing and/or NER promoting activity is herein understood to mean a polypeptide that is capable of stabilizing TFIIH as determined in a functional assay, preferably the assay herein provided in example 4, and/or active in NER
promoting activity as determined by a functional NER assay and/or an assay specific for the TCR
subpathway, preferably the assay provided in example 3. A further functional assay for TFIIH stabilizing and/or NER promoting activity is provided by complementation of TTD-A cells (i.e. TTD cells that belong to the TTD-A complementation group). A polypeptide with TFIIH
stabilizing and/or NER promoting is herein understood to be capable of correcting the DNA repair defect of TTD-A cells, e.g. by microinjection of the polypeptide or a nucleic acid construct capable of expressing the polypeptide.
"Sequence identity" is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988;
Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heine, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M
Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J.
Applied Math., 48:1073 (1988).
Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available Mc(.arthn Turm~h LLI' TDO-RED #8236510 0. l computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, BLASTP, BLASTN, and FASTA
(Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990). The BLAST X program is publicly available from NCBI
and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894;
Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.
Preferred parameters ,for polypeptide sequence comparison include the following:
Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix:
BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-( 1992); Gap Penalty: 12; and Gap Length Penalty: 4. A program useful with these parameters is publicly available as the "Ogap" program from Genetics Computer Group, located in Madison, WI. The aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
Preferred parameters for nucleic acid comparison include the following:
Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: matches=+10, mismatch=0;
Gap Penalty: 50; Gap Length Penalty: 3. Available as the Gap program from Genetics Computer Group, located in Madison, Wisconsin. Given above are the default parameters for nucleic acid comparisons.
Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called "conservative" amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valise, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; a group of amino acids having acidic side chains is aspartic acid and glutamic acid and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
Preferred conservative amino acids substitution groups are: valise-leucine-isoleucine, McC artho Tetrault LLl' TDO-RED #d?3G5l0 v. !
phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gln or his; Asp to glu; Cys to ser or ala; Gln to asn; Glu to asp; Gly to pro; His to asn or gln;
Ile to leu or val; Leu to ile or val; Lys to arg; gln or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser;
Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
Nucleic acid sequences encoding polypeptides having TFIIH stabilizing activity and/or NER promoting activity may also be defined by their capability to hybridise with the (complementary strand of) the nucleotide sequence of SEQ ID NO: 2, preferably under moderate, or more preferably under stringent hybridisation conditions.
Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0,1 M salt, or less, preferably 0,2 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having about 90% or more sequence identity.
Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least SO nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M
salt, preferably 6 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is perforned for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence A~IcCar~h~= Tetrnul~ LLP TDO-RED #8236510 n. I
_g_ identity. The person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 99%.
The nucleic acid molecules of the invention preferably encode a polypeptide with TFIIH
stabilizing and/or NER promoting activity that is a mammalian, preferably a human TTDA
protein or a murine TTDA protein.
In a further aspect, the invention relates to a nucleic acid probe comprising a part of a nucleotide sequence that has at least 90% with a nucleotide sequence as depicted in SEQ ID NO:
2, or its complement sequence. Preferably, the probe comprises a part of a nucleotide sequence that has at least 90% with a nucleotide sequence as depicted in SEQ ID NO: 2 from positions 1 to 331 more preferably from positions 60 to 275. Nucleic acid probes are used to analyse nucleic acids encoding the polypeptide having TFIIH stabilizing and NER promoting activity. Such analysis may include the analysis of the genotype of a subject with respect to sequence encoding TTDA, e.g. the presence or absence of specific mutations or alleles, or may involve analysis of the expression of nucleic acids encoding TTDA. The subject may be a mammal and preferably is a human. Such analyses may be performed for diagnostic purposes (see below).
Nucleic acid probes thus include poly- and oligonucleotides for use as hybridisation probes, as primers for sequencing or amplification and for use in techniques such as Oligonucleotide Ligation (-Amplification) assays (see e.g. US 4,988,617; US 5,876,924; WO 96/15271; and WO 97/45559) or Single-Strand Conformational Polymorphism assays (see e.g. Orita et al., 1989, Genomics 5:
874-879). For further nucleic acid analysis techniques reference is made to Sambrook and Russell (2001, Molecular Cloning: A Laboratory Manual, 3~d edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY). A preferred nucleic acid probe is a probe that comprises at least 10, 12, 14, 16 or 20 contiguous nucleotides of a nucleotide sequence that has at least 70, 80 or 90% identity with a nucleotide sequence as depicted in SEQ
ID NO: 2, which spans the entire coding sequence of the human hTFBS / TTDA gene. Probes derived from SEQ
ID NO: 2 or the genomic TTDA locus, SEQ ID. NO. 3, 4 and 5, may thus be used to analyse both exonic and intronic sequences as well as non-coding sequence up- or downstream from the transcription unit that may be involved in the regulations of expression of the TTDA / hTFBS
gene. A probe according to the current invention comprising a stretch of nucleic acids may be A~IcC'crrlhr Tewcrult LLT' TDO-RED #82365/0 n. I
advantageously physically linked to a solid support, such as, but not limited to, a DNA (micro-) array.
In another aspect the invention relates to a vector comprising a nucleic acid molecule or probe as defined above. Preferably the vector is a replicative vector comprising an origin of replication (or autonomously replication sequence) that ensures multiplication of the vector in a suitable host for the vector. Alternatively the vector is capable of integrating into the host cell's genome, e.g. through homologous recombination, random integration or otherwise.
A particularly preferred vector is an expression vector that wherein a nucleotide sequence encoding a polypeptide with TFIIH stabilizing and/or NER promoting activity as defined above, is operably linked to a promoter capable of directing expression of the coding sequence in a host cell for the vector.
As used herein, the term "promoter" refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A "constitutive" promoter is a promoter that is active under most physiological and developmental conditions. An "inducible" promoter is a promoter that is regulated depending on physiological or developmental conditions. A "tissue specific" promoter is only active in specific types of differentiated cells/tissues.
Expression vectors allow the polypeptides with TFIIH stabilizing and/or NER
promoting activity of the present invention to be prepared using recombinant techniques in which a nucleotide sequence encoding the polypeptide of interest is expressed in suitable cells, e.g.
cultured cells or cells of a multicellular organism, such as described in Ausubel ed., "Current Protocols in Molecular Biology", Greene Publishing and Wiley-Interscience, New York (2003) and in Sambrook and Russell (2001, supra); both of which are incorporated herein by reference in their entirety. Also see, Kunkel (1985) Proc. Natl. Acad. Sci. 82:488 (describing site directed McC'nrth> Teu-ault LLI' TDO-RED #8236510 v. l mutagenesis) and Roberts et al. (1987) Nature 328:731-734 or Wells, J.A., et al. (1985) Gene 34:315 (describing cassette mutagenesis).
Typically, nucleic acids encoding the desired polypeptides are used in expression vectors.
The phrase "expression vector" generally refers to nucleotide sequences that are capable of affecting expression of a gene in hosts compatible with such sequences. These expression vectors typically include at least suitable promoter sequences and optionally, transcription termination signals. Additional factors necessary or helpful in effecting expression can also be used as described herein. DNA encoding a polypeptide is incorporated into DNA
constructs capable of introduction into and expression in an in vitro cell culture. Specifically, DNA constructs are suitable for replication in a prokaryotic host, such as bacteria, e.g., E.
coli, or can be introduced into a cultured mammalian, plant, insect, e.g., Sf~, yeast, fungi or other eukaryotic cell lines.
DNA constructs prepared for introduction into a particular host typically include a replication system recognised by the host, the intended DNA segment encoding the desired polypeptide, and transcriptional and translational initiation and termination regulatory sequences operably linked to the polypeptide-encoding segment. A DNA segment is "operably linked"
when it is placed into a functional relationship with another DNA segment. For example, a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence. DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide. Generally, DNA
sequences that are operably linked are contiguous, and, in the case of a signal sequence, both contiguous and in reading phase. However, enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
The selection of an appropriate promoter sequence generally depends upon the host cell selected for the expression of the DNA segment. Examples of suitable promoter sequences include prokaryotic, and eukaryotic promoters well known in the art (see, e.g.
Sambrook and Russell, 2001, supra). The transcriptional regulatory sequences typically include a heterologous enhancer or promoter that is recognised by the host. The selection of an appropriate promoter depends upon the host, but promoters such as the trp, lac and phage promoters, tRNA
promoters and glycolytic enzyme promoters are known and available (see, e.g. Sambrook and Russell, 2001, McCartht: Terraol~ LLP TDO-RED #823GSI0 v. l supra). Expression vectors include the replication system and transcriptional and translational regulatory sequences together with the insertion site for the polypeptide encoding segment can be employed. Examples of workable combinations of cell lines and expression vectors are described in Sambrook and Russell (2001, supra) and in Metzger et al. (1988) Nature 334: 31-36.
For example, suitable expression vectors can be expressed in, yeast, e.g.
S.cerevisiae, insect cells, e.g., Sf9 cells, mammalian cells, e.g., CHO cells and bacterial cells, e.g., E. coli.
In vitro mutagenesis and expression of mutant proteins are described generally in Ausubel et al. (2003, supra) and in Sambrook and Russell (2001, supra). Also see, Kunkel (1985, supra;
describing site directed mutagenesis) and Roberts et al. (1987, supra;
describing cassette mutagenesis).
Another method for preparing polypeptides is to employ an in vitro transcription/translation system. DNA encoding a polypeptide is cloned into an expression vector as described supra. The expression vector is then transcribed and translated in vitro. The translation product can be used directly or first purified. Polypeptides resulting from in vitro translation typically do not contain the post-translation modifications present on polypeptides synthesised in vivo, although due to the inherent presence of microsomes some post-translational modification may occur. Methods for synthesis of polypeptides by in vitro translation are described by, for example, Berger & Kimmel, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques, Academic Press, Inc., San Diego, CA, 1987.
In a further aspect the invention thus relates to a host comprising a vector as defined above.
The host cells may be prokaryotic or eukarotic host cells as indicated above.
The host cell may be a host cell that is suitable for culture in liquid or on solid media.
Alternatively, the host cell is a cell that is part of a multicellular organism such as a transgenic plant or animal, preferably a non-human animal.
A further aspect the invention relates to a method for producing a polypeptide with TFIIH
stabilizing activity and/or NER promoting activity. The method comprises the step of culturing a host cell as defined above under conditions conducive to the expression of the polypeptide.
Optionally the method may comprise recovery the polypeptide. The polypeptide may e.g. be recovered from the culture medium by standard protein purification techniques, including a variety of chromatography methods known in the art per se.
McCczrtho Tetranlt LLP TDO-RED #82365/0 v. 1 Another aspect of the invention relates to a transgenic animal comprising in its somatic and germ cells a vector as defined above. The transgenic animal preferably is a non-human animal.
Methods for generating transgenic animals are e.g. described in WO 01157079 and in the references cited therein. Such transgenic animals may be used in a method for producing a polypeptide with TFIIH stabilizing activity and or NER promoting activity, the method comprising the step of recovering a body fluid or tissue from a transgenic animal comprising the vector or a female descendant thereof, wherein the body fluid contains the polypeptide, and, optionally recovery of the polypeptide from the body fluid. Such methods are also described in WO 01/57079 and in the references cited therein. The body fluid containing the polypeptide preferably is blood or more preferably milk. In another embodiment the transgenic animal may be a knock out animal, wherein the endogenous TTDA alleles) have been replaced with a dysfunctional or mutated alleles) via homologous recombination techniques known in the art.
For instance the TTDA reading frame may be deleted or disrupted by insertion of a sequence and/or fused to selectable marker Neomycin R(esistance), Hygromycin R, DHFR, puromycin R, HSVtk or reporter genes such as luciferase. Also bi-cistronic messengers of TTDA and a marker allele maybe constructed using an IRES sequence. In other embodiments conditional knock outs or knock in animals may be constructed using the Cre-Lox or Frt/Flp recombinase systems known in the art. In yet another embodiment the transgenic animal may be a knock-in animal in which one or both copies of the TTDA alleles are replaced by sequences coding for tagged forms of TTDA. Various tags that are suitable for fusion with the TTDA reading frame, including e.g.
fluorescent proteins such GFP and variants thereof, as well as affinity tags, are well known in the art (see below). In yet another embodiment RNA interference (RNAi) strategies known in the art and RNAi molecules may be applied to inactivate expression of TTDA locally or systemically in a mammal or in cells.
A further aspect of the invention relates to a polypeptide polypeptide with TFIIH
stabilizing activity and or NER promoting activity and comprising an amino acid sequence having at least 80, 90, 95, 98 or 99% identity with the amino acid sequence of SEQ ID NO: 1.
The polypeptide is further preferably as described above. Included within the scope of the invention are mutant polypeptides having TFIIH stabilizing activity and or NER
promoting activity with e.g. altered specificity or additional features, such as but not limited to fusions to McC.'czrtha= Tetrnult LLP TDO-RED #823GSI0 v. I
molecular tags that may be used for (but not limited to) purification/isolation, identification, visualizatioWlocalization o'r immunization purposes. The amino acid sequence of SEQ ID No. 1 may be fused to an HA, FLAG, myc, multiple-His, double HA, tubulin, GST, protein A, MBP, biotin or any other tag known in the art. Also fluorescent tags may be advantageously applied, S such as GFP, EGFP, eCFP, eYFP, dsRed, RFP, GFP2, FLASH, SNAP and other fluorescent protein tags, or tags that bind specifically to fluorescent small molecular entities, quantum dots or any molecules known in the art. Based on the specific activities of TTDA in stabilizing TFIIH, promoting NER and TCR and promoting DNA transcription, the skilled person will know how to modify essential amino acids by minor amino acid substitutions and or deletions, insertion and fusions to alter its cellular activities, increase or decrease affinities for its natural or artificial binding partners in the TFIIH complex, increase the half life of the protein, fuse it to tags or fluorescent reporters as mentioned above. The tertiary structure of a TTDA
protein based on the enzyme depicted in SEQ ID NO: 1 may be altered applying the same principle as above to adapt the structure to modulate the structure of the interaction sites of the protein and subsequently assay the mutant for its TFIIH stabilizing activity and/or its promoting activity for NER, TCR
and DNA transcription.
Another aspect of the invention relates to an antibody or antibody-fragment that specifically binds to a polypeptide with TFIIH stabilizing and/or NER
promoting activity as defined above. Methods for generating monoclonal or polyclonal antibodies or antibody-fragments that specifically binds to a given polypeptide are described in e.g.
Harlow and Lane ( 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) and WO 91/19818; WO 91/18989; WO 92/01047; WO 92/06204; WO
92/18619;
US 6,420,113 and W002/085944 and references cited therein, and comprise VL, VH, scFv, Fab, Fab2 fragments as well as camelid single chain antibodies or antibodies or antibody-fragments from phage-display libraries. The term "specific binding," as used herein, includes both low and high affinity specific binding. Specific binding can be exhibited, e.g., by a low affinity antibody or antibody-fragment having a Kd of at least about 10-4 M. Specific binding also can be exhibited by a high affinity antibody or antibody-fragment, for example, an antibody or antibody-fragment having a Kd of at least about of 10-7 M, at least about 10-8 M, at least about 10-9 M, at least about 10-10 M, or can have a Kd of at least about 10-11 M or 10-12 M or A4cC'artho Tetrnult LLP TDO-RED #8236,110 v. I
greater. Antibodies may be raised in any mammal, and antibodies may preferably be humanized or deimmunized.
Another aspect of the invention relates to microarrays (or other high throughput screening devices) comprising the nucleic acids or polypeptides as defined above. A
microarray is a solid support or carrier containing one or more immobilised nucleic acid or polypeptide fragments for analysing nucleic acid or amino acid sequences or mixtures thereof (see e.g.
7, WO
97/22720, WO 97/43450, EP 0 799 897, EP 0 785 280, WO 97/31256, WO 97/27317, WO
98/08083 and Zhu and Snyder, 2001, Curr. Opin. Chem. Biol. 5: 40-45).
Microarrays comprising the nucleic acids may be applied e.g. in methods for analysing TTDA genotypes as indicated below. Microarrays comprising polypeptide may be used for detection of suitable candidates of TTDA mutants with altered affinities for binding partners or altered activities.
In another aspect the invention relates to method for analysing the NER status or genotype of a subject, a tissue sample or cell or cell-line, in particular its TTDA /
hTFBS genotype.
Analysing the NER status genotype is herein understood to mean analysing whether or not a 1 S genetic defect is present in the sample that underlies a defect in TFIIH
stability and/or levels, a defect in DNA transcription, a defect in NER in general and in particular a defect in the TCR
subpathway. The method preferably comprises the use of a nucleic acid molecule or probe or antibody as defined above. The method preferably is a method for diagnosing a TTD deficiency.
Alternatively, the method for diagnosing a DNA transcription deficiency or NER
/ TCR
deficiency is a method, which comprises the use of an antibody or antibody-fragment as defined above.
In another aspect the invention relates to an expression vector as defined above, wherein the vector is a vector that is suitable for gene therapy. Vectors that are suitable for gene therapy are described in Anderson 1998, Nature 392: 25-30; Walther and Stein, 2000, Drugs 60: 249-71;
Kay et al., 2001, Nat. Med. 7: 33-40; Russell, 2000, J. Gen. Virol. 81: 2573-604; Amado and Chen, 1999, Science 285: 674-6; Federico, 1999, Curr. Opin. Biotechno1.10: 448-53; Vigna and Naldini, 2000, .I. Gene Med. 2: 308-16; Marin et al., 1997, Mol. Med. Today 3:
396-403; Peng and Russell, 1999, Curr. Opin. Biotechnol. 10: 454-7; Sommerfelt, 1999, J.
Gen. Virol. 80: 3049-64; Reiser, 2000, Gene Ther. 7: 910-3; and references cited therein. The vectors are preferably formulated in a phamaceutical composition comprising a suitable pharmaceutical carrier as McC.'artln- Tetrault LLP TDO-RED #823651 D o. I
defined below. lVJethods for preparing administrable compositions are well known in the art and described in more detail in'various sources, including, for example, Remington: The Science and Practice of Pharmacy by Alfonso R. Gennaro, published by Lippincott Williams &
Wilkins; 20th edition, June 1, 2003.
S In a further aspect the invention relates to the use of a vector suitable for gene therapy as defined above in the manufacture of a medicament for the treatment of a NER, TCR of DNA
transcription deficiency, in particular a genetic defect in the TTDA gene.
Similarly the invention relates to a method for treating a TTDA genetic defect and/or a TFIIH
stabilizing deficiency, wherein the method comprising the step of administering to a subject suffering from a TTDA
deficiency, a pharmaceutical composition comprising a vector suitable for gene therapy as defined above, in an amount effective to overcome the deficiency.
The invention further relates to a pharmaceutical preparation comprising a polypeptide with TTDA stabilizing and NER, TCR and DNA transcription promoting activity as defined above. The composition preferably comprises a pharmaceutically acceptable carrier. In some methods, the polypeptide with TFIIH stabilizing activity purified from mammalian, insect or microbial cell cultures, from milk of transgeriic mammals or other source is administered in purified form together with a pharmaceutical carnet as a pharmaceutical composition. The preferred form depends on the intended mode of administration and therapeutic application. The pharmaceutical carrier can be any compatible, non-toxic substance suitable to deliver the polypeptides to the patient. Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions.
For oral administration, the active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. Active components) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like. Examples of additional inactive ingredients that may be added to provide desirable colour, taste, stability, buffering capacity, dispersion or other known desirable features are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the rl~lc(~artlm Temcrul~ LLP TDO-RED #8236510 v. 1 like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain colouring and flavouring to increase patient acceptance. Methods for preparing administrable compositions are well known in the art and described in more detail in various sources, including, for example in Remington: The Science and Practice of Pharmacy by Alfonso R. Gennaro, published by Lippincott Williams & Wilkins; 20th edition, June 1, 2003.
Description of the figures Figure 1.
TTDA (hTFBS) is part of the TFIIH complex.
a. Immunoprecipitation (LP.) assays. Lane 1: molecular weight marker; lane 2-4: whole I S cell extracts (WCE) from MRCSSV (wt), TTD-A and TTD-A + p8; lane 5-6 LP.
from TTD-A and TTD-A + p8 cells extracts. Right panel: 18% SDS-PAGE gel on which are loaded 10 pg of proteins from WCE's and the a-p44 LP. cell extracts from TTD-A
and TTD-A + p8. The blot was immuno-stained with a -HA; the arrow shows the immuno-stained band corresponding to the HA-tagged p8. Middle and Left panel: 11% SDS-PAGE gels on which are loaded WCE and the a -HA LP. cell extracts from TTD-A
and TTD-A + p8. The blots were immuno-stained respectively with a-XPB and a -cdk7;
the arrows show the corresponding immuno-stained proteins.
b. The polypeptide p8 contained in the highly purified TFIIH from a HAP
column, co-purifies with the other nine identified components as shown at the top of the panel (silver staining of an 15% SDS-PAGE and immuno-blot) and with TFIIH transcription and repair activities. Lower panel: immuno-blotting identifies p8 in HAP
fractions. A rabbit polyclonal antibody raised against the C-terminal end of p8 was used for the detection of p8 in the HAP fractions containing TFIIH.
c. MALDI-MS identification of p8. Upper panel: P8 identification by MALDI
peptide mass fingerprinting. In the table the experimentally determined values as well as the ,McCarthv Tctrault LLP TDO-RED #823GS10 v. I
corresponding theoretical masses of p8 tryptic peptides are listed. Mass accuracy (ppM) and amino acidic sequences are also shown for each peptide. Middle panel:
Schematic representation of MALDI peptide fingerprinting results. P8 has been identified as CG14037 gene product in NCBI database Figure 2.
Correction of the DNA-repair deficiency of TTD-A by hTFBS.
a. Microneedle injection of an expression vector containing the wt cDNA of hTFBS (p8) in TTD99R0 (TTD-A) primary fibroblasts. Micrographs show the effect of p8 expression on DNA repair activity. Injected polynucleated primary fibroblasts (2), indicated by the arrow, exhibit a high (wild-type) level of UV-induced UDS, as apparent from the number of silver grains above their nuclei, when compared to the non-injected surrounding TTD-A fibroblasts (1), which express low residual UDS levels typical for TTD-A.
LTDS
correction by p8 microinjection was also observed when injected into the other TTD
group A cells, TTD1BR and TTD13PV (not shown).
b. Table summarizing the mutations found in the four cell lines analyzed derived from three unrelated TTD-A cases. In bold the mutated base in the codon.
Figure 3.
Nucleotide excision repair characteristics of TTDA.
a. UV-survival using wild-type MRCSSV (closed black diamonds), TTD1BRSV
(closed red triangles) and a cell population of TTD1BRSV expressing TTDA-HA (closed green squares). The percentage of surviving cells is plotted against the LTV-C dose, in J/mZ.
b. Locally UV-irradiated (40J/m2) TTDA-HA expressing TTD1BRSV are stained with a-HA (left panel) and a-XPB (right panel) antibodies. Locally damaged areas are indicated by the arrows.
c. TFIIH HAP fraction 6 (1 ~,1) was pre-incubated with either no antibody (lane 1), or increasing amounts of Ab-p8 (1, 5 and 10 pg; lanes 2-4 respectively), or Ab control (l, 5 and 10 fig; lanes 5-7 respectively) before being supplemented with all other NER factors;
McC anthy Turnuh LLI' TDO-RED #8236510 v. I
XPC-hR23b, XPA, RPA, XPG and ERCC1-XPF in addition to damaged DNA to measure dual incision.
Figure 4.
Recovery of reduced concentrations of TFIIH in TTD-A fibroblasts expressing TTDA-HA.
a. Mass population of TTD1BRSV expressing TTDA-HA. Cells expressing TTDA-HA
(left panel) show an increased level of XPB protein (right panel).
b. Mass population of TTD1BRSV expressing TTDA-HA. ERCC1 levels (right panel) are not influenced by TTDA-HA expression (left panel).
c. TTDA-HA expressing MRCSSV cells (left panel) show an increased level of XPB
protein (right panel).
Figure 5.
Primary amino acid sequence alignment of human TFBS with its homologs, showing conserved homology of hTFBS along evolutionary lines. Alignment. Displayed are TFBS
homologs in H.
Sapiens, M. musculus, A. thaliana, the C. elegans (all 71 aa), C. reinhardtii (78 aa), S. pombe (68 aa) and S. cerevisiae homolog (72 aa). Identical amino acids are in dark shaded boxes and physico-chemically related residues are in light shaded boxes.
A9c(-nrzht: Tezrnulz LLI' TDO-RED #8236510 n. l Examples Isolation and characterisation of cDNA and ~enomic clones encoding a human ortholo~ue of yeast TFBS.
Example 1 Cloning of hTFBS/TTDA
We cloned the human TFBS cDNA from primary fibroblasts by virtue of its homology with yeast TFBS using conventional techniques known in the art. An HA-tagged version of hTFBS (p8-HA) was constructed via conventional molecular cloning methods (Maniatis et al, supra) and expressed in TTD-A fibroblasts and subsequently used for immuno-precipitations with anti-HA (Figure 1 a). Both the XPB core TFIIH and the associated CAK
component (CDK7) were co-precipitated with p8-HA, in contrast to replication/repair factor RPAl (data not shown). Conversely, anti-p44 (another core-TFIIH component) co-precipitated p8-HA. We conclude that, analogous to yeast, this small polypeptide is associated with TFIIH in mammalian cells.
We further analyzed the association of p8 with TFIIH using - purified TFIIH
from HeLa cells (Gerard, M. et al., J. Biol. Chem. 266, 20940-20945, 1991). Silver-staining revealed that a protein-band of ~8 kDa co-purified with the other TFIIH subunits and with the transcription and DNA repair activities (Figure lb). MALDI peptide mass fingerprint analysis on tryptic digests of this ~ 8 kDa band showed that all identified peptides were part of hTFBS
(Figure 1 c). Finally, immuno-blotting using a polyclonal antibody raised against this 8 kDa polypeptide showed that it co-purifies with TFIIH (Figure 1B). These experiments unambiguously recognized this polypeptide as the human ortholog of TFBS and as a genuine, novel tenth component of TFIIH.
To confine that hTFBS is the gene affected in TTD-A, we microinjected the cDNA
into polynucleated TTD-A fibroblasts and determined the DNA repair capacity of injected cells by measuring UV-induced UDS (unscheduled DNA synthesis). Figure 2a shows a binucleated p8 injected cell (2) with a clearly increased UDS (elevated grain number) as compared to the low UDS in non-injected neighboring TTD-A cells (1). p8 cDNA corrected the repair defect of TTD-A cells to a comparable level as observed in wild-type cells assayed in parallel, indicating that hTFBS (p8) is affected in TTD group A.
JO
MeC'arthn Tetrnrrlt LLl' TDO-RED #82365/0 v.
ExamQle 2 TTDA diagnosis of subjects To verify that hTFB~ is implicated in TTD-A we analyzed genomic DNA of three unrelated TTD-A cases (Table 1 ). All three TTD-A patients showed an inactivating, although distinct, mutation within the hTFBS gene (Figure 2b). Patient TTD99R0 carnes a homozygous CST transition at codon 56, converting CGA (arginine) into a TGA stop codon, truncating the protein by 23%. Siblings TTD13PV and TTD14PV harbor (homozygously) a mutation in the start codon, converting ATG to ACG. This mutation will result in either a complete loss of protein synthesis or the production of an N-terminal truncated polypeptide (lacking the first and most conserved 15 amino acids (21%)), when a downstream AUG at codon 16 is used. Since only one allele was detected, both mutations can be considered functionally homozygous.
Finally, patient TTD1BR appeared a compound heterozygote: one allele being identical to TTD99R0 and the other carrying a TIC transition at codon 21, converting the conserved leucine residue to a proline. Genomic mutations were also identified in isolated mRNA, as revealed by RT-PCR, demonstrating that these alleles are expressed (data not shown). Together our data unambigously identified hTFBS as the NER-defect causing gene in TTD
group A. We designated this novel TFIIH subunit as TTDA (Accession nr. AJ634743).
The TTDA protein and DNA coding sequences provided in the sequence listing, SEQ ID
No 1 and SEQ ID No. 2 respectively, provide means to diagnose subjects for the presence of a gene defect in the TTDA gene. Detection of gene defects may be performed by various methods known in the art, in situ or in vitro on specimens from a subject such as but not limited to tissue samples, blood samples, hair samples, faeces, urine, saliva. Various techniques may be applied for mutation analysis of TTDA in a subject, such as but not limited to: DNA
sequencing of genomic DNA or cDNA, PCR or Nasba analysis, analysis using Southern blotting, expression analysis using northern or western blotting, DNA microarray or protein microarray analysis, SAGE analysis, EST or SNP analysis.
Example 3 TTDA involved in NER repair, an assay for TTDA activity To further explore the role of TTDA in NER we generated TTD1BR-SV cells stably expressing HA-tagged TTDA. Exposure of the TTDA-HA expressing cells to UV-C
light (Figure 3a) clearly showed that the cells exhibit a UV-sensitivity level comparable to NER
A~1~~C'arthr Tetrault LLP TDO-RED #823GS10 n. I
proficient cells assayed in parallel. Using an assay in which UV-damage is locally inflicted in cell nuclei by irradiation through a filter that contains (S pm) pores, we demonstrated previously that TFIIH components transiently accumulate at these sites (Mone, M.J. et al., EMBO Rep. 2, 1013-10117, 2001, Volker, M. et al., Mol. Cell 8, 213-224, 2001 and Hoogstraten, D. et al, Mol.
Cel. 10, 1163-1174, 2002). We applied the same procedure on TTDA-HA expressing cells to test participation of TTDA in the NER reaction in vivo. At local damaged sites, marked by the accumulation of endogenous XPB, TTDA-HA also accumulated (Figure 3b). This indicates that TTDA participates in the NER reaction similarly to other NER factors (Rademakers, S. et al., Mol. Cell. Biol. 23, 5755-5767, 2003).
We further developed an assay for testing the involvement of TTDA in NER in a reconstituted in vitro incision/excision repair assay, using recombinant NER
factors, purified TFIIH and a plasmid containing a cisplatin-adduct. Addition of increasing amounts of purified anti-TTDA (p8) polyclonal antibodies incubated with a fixed amount of purified TFIIH clearly inhibited the repair reaction, whereas treatment with pre-immune serum had no effect (Figure 1 S 3c). In conclusion, these results demonstrate that TTDA participates, as a part of TFIIH, in NER.
Moreover, a functional assay is here provided which allows testing of TTDA
protein preparations and TTDA proteins that are mutated or chemically or post translationally modified, for NER promoting activity. The reconstituted in vitro incision/excision repair assay described above (and as previously described in Shivji et al., 1999, Methods Mol. Biol, 113, 373-392) may be stripped / cleared from (endogenous) TTDA proteins using polyclonal or monoclonal antibodies using conventional techniques, for instance binding to immobilized secondary antibodies or immobilized protein A or protein G. Subsequently TTDA proteins, in particular variants forms thereof as described herein above, from various sources and preparations, chemically synthesized, in vitro translated preparations or purified TTDA from in vivo sources such as micro organisms, plants or animals, may be assayed for their NER
promoting activity in the in vitro repair reaction of the reconstitution assay.
A~lc(:artho Tctrnttlt LLP TDO-RED #b'23G510 0. !
Example 4 TFIIH stabilization assay The NER defect and TTD-specific features in TTD-A appeared to be linked to a reduced steady-state level of the total amount of TFIIH (Venneulen, W. et al., Nat.
Genet. 26, 307-13, 2000). As shown in Figure 4a, cells that express TTDA-HA have a concomitant higher XPB
level, suggesting that TTDA has a stabilizing function and protects TFIIH from degradation.
Similar observations were made in cells stairied with antibodies directed against other TFIIH
components, i.e. p62, p44 and CDK7, indicating that the intra-nuclear levels of the entire TFIIH
complex are increased. In contrast, non-TFIIH NER factors (ERCC 1 ) are not increased (Figure 4b). Additionally, in immunoblot experiments (Figure 1 a) elevated levels of XPB and CDK7 wexe also observed after TTDA expression.
These experiments show that the TFIIH concentration depends on the presence of the TTDA protein and hence provide a functional assay for TTDA protein activity.
The assay here provided allows functional testing of TTDA from various sources and preparations, TTDA
mutants, (both naturally occurring mutants and constructed mutants) and modified proteins. We transiently over-expressed TTDA-HA in MRCS (wild-type SV40-immortalized). Even in these TTDA-proficient cells transient over expression of the TTDA gene appeared to increase the cellular TFIIH content (Figure 4c), showing that TTDA expression regulates TFIIH
concentration in vivo. Overexpression of (functional) TTDA genes in TTDA-deficient cells enhances the relative TFIIH stabilization effect, whereas dysfunctional TTDA
mutants have a diminished effect or no effect, depending on the residual activity of the mutant.
One of the most obvious cellular phenotypes of cultured TTD-A cells is the severely reduced level (~ 30%) of TFIIH (Table 1). The fact that TTDA transiently increases the level of TFIIH even in wild-type cells (Figure 4c) demonstrates that this 8 kDa protein is involved in regulating steady-state levels of TFIIH. Because mRNA levels of TFIIH
components are not reduced in TTD-A cells (Vermeulen et al, 2000 supra), controlling the amounts of TFIIH by TTDA must be post-transcriptional. Regulation at the translational or post-translational level suggests a chaperone-like function of TTDA for complex-assembly or maintenance of the complex stn~cture. An altered tertiary structure of TFIIH, by the absence of TTDA, may impede Loth the longevity of this complex as well as its repair and transcription activity.
NcC artlro Tetrault LLI' TDO-RED #8236510 v. I
Although striking parallels on TFIIH composition, structure and functioning (Table 2) can be drawn between man and yeast, differences in TFBS's relative contribution to transcription efficiency are also observed. In yeast the absence of TFBS appeared to affect the efficiency of transcription and NER, whereas in man TTDA mutations affect transcription to some extent (Tirode, F., Busso, D., Coin, F. & Egly, J.M., Mol. Cell 3, 87-95, 1999).
Furthermore, in man the absence of TTDA appeared to predominantly affect TFIIH stability and or steady-state levels, whereas in yeast, absence of TFBS did not reduce TFIIH levels.
The severe effect on NER functioning suggests that NER requires higher concentrations of TFIIH than transcription. Recent live cell studies, showed that TFIIH
participates significantly longer in NER than in transcription (Hoogstraten, D. et al., Mol. Cel. 10, 1163-1174, 2002), providing a possible explanation for the increased need for sufficient amounts of TFIIH in NER.
Additionally, an altered structure of TFIIH by mutated TTDA may mainly affect the NER
function.
In conclusion, the identification of TTDA as a novel, evolutionarily conserved, tenth subunit of TFIIH provides essential information to understand the molecular mechanism of TFIIH function in DNA repair, transcription, and human disease. These findings unambiguously identify TTDA as the NER-defect causing gene in TTD group A, and provide an opportunity to diagnose and treat disorders caused by insufficient cellular levels of TFIIH, which may lead to deficiency in pol I and pol II DNA transcription, NER deficiency and in particular TCR
deficiency in a subject.
Methods and materials Cloning. For molecular cloning techniques general reference is made to Sambrook and Russell, 2001, Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY, and to Current Protocols in Molecular Biology, F.M. Ausubel ed., published by John Wiley & Sons Inc., December 2003. Nucleic acid modifying enzymes, hits, equipment and automated DNA synthesisers were used according to the manufacturer's 111StT'LlCt1011S.
McCcrrthv Tetnatrlt LLP TDO-RED #8?365/0 a. I
Cell lines, culture conditions and transfections. Primary human fibroblasts TTD99R0, TTD1BR, TTD13PV, TTD14PV (all TTD-A) and CSRO (wild type, NER-proficient) were cultured under standard conditions at 37°, 5% COz and 3% oxygen in Ham's F-10 medium (supplemented with 12% FCS and antibiotics (penicillin and streptomycin). SV-40 transformed cell lines TTD1BR-SV (TTD-A) and MRCS-SV (wild type) were cultured at 37°, 5% C02 in a 1:1 mixture of F-10 and DMEM (Gibco) supplemented with 8% FCS and antibiotics.
C-terminally HA-tagged TTDA was cloned into the expression vector pCDNA3 (Invitrogen), this construct was transfected into TTD1BRSV fibroblasts using FUGENE 6 transfection reagent (Roche).
Transfectants were submitted to triple ultraviolet-C irradiation of 8J1m2 with two-days intervals to enrich the population of TTDA-HA expressing cells. One week after the last irradiation stable transfectants were single cell sorted (FACSVantage, Becton Dickinson, Belgium). Single cell derived colonies were tested on the expression of the fusion gene by anti-HA
immunofluorescence. A
selected clone, stably expressing TTDA-HA was tested for its repair capacity (UV-survival, see below).
Immunoprecipitation and immunoblot analysis. Whole cell extracts from MRCSSV, TTD1BRSV and TTD1BRSV+hTFBSHA were prepared by isolating cells from 6 petri dishes per cell line (13 Cnl). Collected cell-pellets were washed once in PBS prior to lysis by Bouncing (20 strokes using a 12.61 mm Bounce homogenizer, Bellco Glass, INC., USA) in 2 ml of buffer A (SOmM Tris pH 7.9; 150 mM NaCI; 20% Glycerol; 0.1 % NP40; SmM (3-mercaptoethanol) supplemented with anti-proteases. Cellular extracts from MRCSSV, TTD1BRSV and TTD1BRSV+hTFBSHA were incubated overnight at 4°C in buffer A with respectively anti-HA
(12CA5) and anti-p44 (1H5) anti-bodies cross-linked to protein A-sepharose beads (Amersham Biosciences, UK). Prior to immuno-precipitations, cross-linked beads were washed 3 times in buffer A. After incubation with the extracts beads were extensively washed with buffer A, prior to analysis by SDS-PAGE and immunoblotting using anti-XPB (1B3), anti-cdk7 (2F8) and anti-HA (3F10).
Mass spectrometry.
McC.'artlr~: Tetrntrlt LLP TDO-RED #8236510 v, l TFIIH subunits were separated on a 15% polyacrylamide SDS-PAGE and silver stained (Rabilloud, T. Silver staining of 2-D electrophoresis gels. Methods Mol. Biol.
112, 297-305, 1999). The band migrating below the 10 kDa marker was excised and in gel-digested with trypsin (Cavusoglu, N., Brand, M., Tora, L. & Van Dorsselaer, Proteomics 3, 217-223, 2003).
Peptide extracts were speed-vac concentrated, chromatography purified on a C18 reverse-phase "ZipTip" pipette tip (Millipore) and finally eluted in 2 pl of acetonitrile 50%. 0.5 p,l of peptides were mixed either with an equal volume of saturated alpha-cyano-4 hydroxycinnamic acid (dissolved in 50% acetonitrile) or with a same volume of saturated 2,5-dihydroxybenzoic acid (dissolved in 20% acetonitrile). Both matrices were purchased from LaserBio Labs. Mass measurements were carried out on a Bruker Reflex IV MALDI-TOF spectrometer in the positive-ion reflector mode. The mass acquisition range was 800-3000 Da with a low mass gate set at 700 Da. Internal calibration was performed using autolytic trypsin peptides (MH+ with m/z = 842.51, 2211.11 and 2807.47). Mono-isotopic peptide masses were assigned manually using the Bruker X-TOF software. Database searches (NCBI, proteins of human origin), using parameters: MW between 0-10 kDa; trypsin digestion (one missed cleavage tolerated), cysteines modified by carbamidomethylation, methionine oxidation and mass tolerance of 75 ppM, were performed with the Profound program (ht~://prowl.rockefeller.edu/): 4 out of S
p8 peptides were detected in the MALDI spectrum using both alpha-cyano-4 hydroxycinnamic (data not shown) and 2,5-dihydroxybenzoic acids as matrix Microneedle injection and DNA repair assays. HTFBS cDNA constructs (with and without HA-tag) were microinjected into TTD-A fibroblasts (TTD99R0, TTD1BR) as described (Venneulen, W. et al,. Am J Hum. Genet. 54, 191-200, 1994). Briefly, 3 days prior to microinjection cells were fused using inactivated Sendai virus and seeded onto coverslips. 24 hrs after injection, to allow the expression of the injected gene, cells were exposed to 15 J/mZ
UV-C and incubated for 2 hr in culture medium supplemented with 3H-thymidine.
After removing the excess of free 3H-thymidine, cells were fixed. DNA repair capacity (UV-induced unscheduled DNA repair synthesis or UDS) was determined as the amount of autoradiographic grains above the nuclei, which is usually severely reduced in NER-deficient cells (for details see Venneulen, W. et al., Nat. Genet. 26, 307-13, 2000).
Nlc( ar7ho Tc%~raul~ LL P TDO-RED #8236510 ~:, l The sensitivity towards ultraviolet light of the TTD1BRSV (TTD-A) fibroblasts, TTD1BRSV+hTFBS-HA (TTD-A corrected) and the NER-proficient MRCSSV (wt) human fibroblasts was determined by 3H-thymidine incorporation, as described previously (Sijbers, A.M. et al., Nucleic Acids Res. 24, 3370-3380, 1996 and van Gool, A.J. et al., Embo J. 16, 5955-5965, 1997).
Mutation analysis on hTFBS gene and cDNA.
Total RNA (lOp.g) was extracted from wild type (CSRO) and TTDA primary fibroblasts (TTD99RO; TTD1 BR; TTD13PV and TTD14PV) using Rneasy Mini columns (Qiagen, USA) and used for preparation of cDNA by reverse transcription. Reverse transcription was performed using the Superscript tm First-Strand Synthesis System for RT-PCR (Invitrogen, USA).
Amplification of hTFBS cDNA was earned out using puReTaqTMReady-To-GoTMPCR
Beads (Amersham, USA) and 10 pmol of primers (Tm: 60°).
The coding region of the genomic hTFBS was amplified by using 2 sets of primers, covering the coding exons 2 and 3. Primers sequences are available on request.
Genomic DNA ( 100-500 ng) was amplified by using puReTaqTMReady-To-GoTMPCR
beads (Amersham, USA) and 10 pmol of each primer set. Amplification products were cloned into T-easy vector (Promega, USA). For each cell line 18 independent clones were sequenced by BaseClear labservices (BaseClear, The Netherlands).
Immunofluorescence. Two days after micro-needle injection or transfection, cells were washed twice in PBS and then fixed in 2% parafonnaldehyde and permeabilized by 2 times 10 minutes rinsing in PBS containing 0.1 % Triton X-100 (PBS-T), followed by washing with PBS+ (PBS+
0.15% glycine and 0.5% BSA). Antibodies, diluted in PBS+ were incubated for 2 h. at RT in a moist chamber, dilutions are: anti-XPB (IB3), 1000x; anti-HA (3F10, Roche), 1000x.
Subsequently, coverslips were washed (Sx; 5 min) in PBS-T, and incubated with the secondary antibody, respectively: goat anti-mouse, Cy3-conjugated (The Jackson Laboratory); goat anti-rat, Alexa 488-conjugated (Molecular Probes), each diluted 1000x in PBS+. After the same washing procedure, coverslips were mounted in Vectashield mounting medium (Vector Laboratories) McCarthv Tetrault L LP TDO-RED #8236510 n. l containing DAPI~(4'-6-diamino-2-phenylindole) at 1.5 pglp,l. Epifluorescent and phase-contrast images were produced on a Leitz Aristoplan microscope equipped with epi-fluorescence optics and a PLANAPO 63x/'1.40 oil immersion lens.
Dual incision NER assay. Dual incision assay was carried out as described previously (Riedl, T., Hanaoka, F. & Egly, J.M., Embo J. 22, 5293-5303, 2003)., in 25 p.l dual incision buffer supplemented with 2mM ATP. Each reaction contained 5ng of XPG, l5ng of XPF/ERCC1, l Ong of XPC-hHR23B, 50rtg of RPA, 25ng of XP~A and TFIIH as indicated. ~
Following 10 min of pre-incubation at 30 °C, 30ng of Pt DNA is added and the reactions are continued for 90 min at 30°C. The excised fragment is detected on 14 % urea-acrylamide after annealing with 9ng of the complementary oligonucleotide and addition of four radio labeled dCMPoc-P3a (3000pCi/mmol) residues by Sequenase V2.1 (USB). Prior to the addition to the repair reactions, TFIIH was preincubated with either p8 polyclonal anti-bodies or pre-immune serum.
The rabbit polyclonal was produced by coupling the peptide VGELMDQNAFSLTQK (57-71) to ovalbumin and injecting it in rabbit.
Local Ultraviolet Irradiation. Cultured cells were UV-irradiated (254 nm) at 40J/m2 through an isopore polycarbonate,filter (Millipore) containing pores of 5 ~m in diameter as described previously (hone, M.J. et al., EMBO Rep. 2, 1013-10117, 2001 and Volker, M. et al., Mol. Cell 8, 213-224, 2001 ). Subsequently, after filter removal cells were fixed with paraformaldheyde and further processed for immuno-cytochemistry as described above.
Accession numbers. The complete human TTDA cDNA sequence is available under BC060317, AK055106 or AJ634743. The human genomic TTDA sequence may be found in the human chromosome 6q25.3 contig, which is available under Hs 356224 and NT-007422, chr. 6 contig Hs_7579.
A4c(-nrtln. Tetrauh i_LP TDO-RED #8236 l0 v. I
nook ~ ~ ~ ~
o o ~ ., ., .
~.c ~z x ~ c~ G x a ~ ~ o o ~ a a ' ~ ~ ' ~ =.
<
-~ o ~ c w C
~ ~ "' ~ n " b c 0 'x ~ ~ ~ z~ ~ g ~ ~ 9 y '' ~~ ~'~~ '~ ~ x ~ ~ n c ~ " ~ ~~ ~
o ~
u ~ ei ...
I o ' ~ ~ b b m G
m " . .
n ~ o ! b . o ' b m m o ~
-. a ~ ~~g ~ ~ ~
~,~b ~ c ~
a ~. -T
w c~
v .
C ~ p ~ N ~ + I I I (]
. +
v a ~ ~ ~, ~ ' a ~ a ar n o~
- a -n o ..i~ o + p I ~ ~ >C ~! n ~
v ~ o ' ~ ~ ci a ~ v Q N o ~ o o '- ~' C : 7C n m C O x c~ b N
CD ~ o d ~
~
b w ~. o + c~ + I ~ yC ~7 -v f ~' ' Q 'v~~O ~ O _ yC
CD a X
~
~ Cn w ~ ~
N o z ~ ' ~ ~ ~. < b b n w'. o m-~ o b , ~ a ~ v 0 o d x Q
il' d x F $
m o ~
~
Q ~ z o ~ sy + ~ 3 ~
U ~ ~ H
o ~ n t x c.: . C7 p n n a a ', a -a a ~' co O n N l N p ~, n +
~
o w J _' a. -, ~ d t o ~ ~
~ O :
~
, . n .
Q
w o ~ fy + I ~
~
II o ~ F c.: n, d d p ~
~
v Q 0 9 w O ''' (D ,...
. ~
cn <
a c am Table 2 TFIIH subunits in mammals and yeast:
predicted % identity subunitMammalian S.CerevisiaeProtein Properties between size human in kDa yeast (human) 1 XPB RAD25/SSL2 89 Helicase, 49 5'-3' 2 XPD RAD3 80 Helicase, 51 3'-5 3 GTF2H1 (hTFB1) TFB1 62 21 4 GTF2H2 SSL1 44 Zn-finger 34 GTF2H3 (hTFB4) TFB4 34 Ring-finger 29 6 GTF2H4 (hTFB2) TFB2 52 34 7 MAT1 (hTFB3) TFB3 32 Ring-finger 31 8 CDK7 KIN28 41 CTD kinase 41 9 Cyclin H CCL1 38 cyclin motifs23 GTF2H5 (hTFBS TFBS* 28 10* l 8 TTDA) Mc( crrtho Tetrault LLP TDO-RED #8?365/0 v. l SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: Universitair Medisch Centrum Rotterdam (ii) TITLE: NOVEL TFIIH SUBUNIT
(iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS:
FILE REFERENCE: T00590-0371-CA
(v) COMPUTER READABLE FORM:
(D) SOFTWARE:
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,471,063 (B) FILING DATE: JULY 6, 2004 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: NONE
(B) FILING DATE: NONE
(2) INFORMATION FOR SEQ. ID NO: l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 71 (B) TYPE: PRT
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (iii) FEATURE:
(A) NAME/KEY: unknown (B) LOCATION: unknown (iv) SEQUENCE DESCRIPTION: SEQ. ID NO: 1:
Met Val Asn Val Leu Lys Gly Val Leu Ile Glu Cys Asp Pro Ala Met Lys Gln Phe Leu Leu Tyr Leu Asp Glu Ser Asn Ala Leu Gly Lys Lys Phe Ile Ile Gln Asp Ile Asp Asp Thr His Val Phe Val Ile Ala Glu Leu Va1 Asn Val Leu Gln Glu Arg Val Gly Glu Leu Met Asp Gln Asn Ala Phe Ser Leu Thr Gln Lys (2) INFORMATION FOR SEQ. ID N0: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 331 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo Sapiens (iii) FEATURE:
(A) NAME/KEY: unknown (B) LOCATION: unknown (iv) SEQUENCE DESCRIPTION: SEQ. ID N0: 2:
ggcgcttctg catctgtggg ccgagcattc ttcaggtcat ctgaaccttc tgagaaaaca 60 tggtcaacgt cttgaaagga gtgcttatag aatgtgatcc tgccatgaag cagtttctgc 120 tgtacttgga tgagtccaat gccctgggga agaagttcat cattcaagac attgatgaca 180 ctcacgtctt tgtaatagca gaattggtta atgtcctcca ggagcgagtg ggtgaattaa 240 tggaccaaaa tgctttttcc cttacccaga aatgaaaata ctcaatatgg accatttagg 300 aattataagc agcaactgtg aaagacttgc c 331 (2) INFORMATION FOR SEQ. ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 89 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (iii) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: unknown (C) OTHER INFORMATION: exon l, non coding, nucl. 22 - 65 (iv) SEQUENCE DESCRIPTION: SEQ. ID NO: 3:
gatggcgtat cggcgaggcg cactctgccg gcaacgccga ggcgcttctg catctgtggg 60 ccgaggtgtg tggcgagcgt ccgagcggc 89 (2) INFORMATION FOR SEQ. ID N0: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo Sapiens (iii) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: unknown (C) OTHER INFORMATION: exon 2 ranges from nucl. 19 to 89 CDS starts at nucl. 55, ATG.
(iv) SEQUENCE DESCRIPTION: SEQ. ID N0: 4:
taccttactc tttttattag cattcttcag gtcatctgaa ccttctgaga aaacatggtc 60 aacgtcttga aaggagtgct tatagaatgg ttagtagttt tgatactgca 110 (2) INFORMATION FOR SEQ. ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1226 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (iii) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: unknown (C) OTHER INFORMATION: exon 3 ranges from nucl. 27 to 1226 CDS ends at nucl. 206, TGA stopcodon (iv) SEQUENCE DESCRIPTION: SEQ. ID N0: 5:
cttacaatca tgtgtttgtc tttacagtga tcctgccatg aagcagtttc tgctgtactt 60 ggatgagtcc aatgccctgg ggaagaagtt catcattcaa gacattgatg acactcacgt 120 ctttgtaata gcagaattgg ttaatgtcct ccaggagcga gtgggtgaat taatggacca 180 aaatgctttt tcccttaccc agaaatgaaa atactcaata tggaccattt aggaattata 240 agcagcaactgtgaaagacttgccactcaatatcttaggtgactgattagacatagaggg300 ttgttttaggagcatgccacgggaaagactgagggatcatgatcatttgttcagaaaaaa360 agcccctgaactgattttgttaccatagaatttaaaaaaaaaaaaagctttaacagttgg420 ctgtaatttggcttttattatcctttattaaaatacaaatgtcaatgcttttcctgcctt480 tttaataccatgtcagtgtaacataggtatttattttgctcatccctgtgatctgtgcat540 ttttgctgcgtggatgtgattgtttggtttcagttagaaacgtcatagatttgctgtttg600 aatatgccaaggtggggacttagacattatgtacgtctcacaaatcctacctgcatacca660 gtcagctctattgaggaagacaatgtaaaactaatgtaaactacagtttgcatttccctg720 aaaacagaatattgtttttaagagggttagaaacaaccagtgggaaaggcacatgctgct780 ttgtttagtttttccttgttcaaactttgttggtcacattttcccatctgtattcttttt840 tattaagaaaacagcttagggaggctgaggtgggaggattgcttgagcccaggagtccga900 ggttgctacaaaaacaccattgcactctggcctggacaacagagagaccctgcctcaaaa960 aaaaaaaaaaaaaaaaaaaaaattctacttgtaccttattccctatgagaatacttatca1020 aacttatctaaaaaagaaaaataggaacagccatatgcaaagtcagcccaacaggaaagg1080 acatattagattaaaatacattgcggcctgggcttagtggctcacacctgtaatcccagc1140 actttgggaggctgaggcaggcagatcgcttgagtccaggagtcgaaaccctgtctctac1200 aaaaaaaaaaatacaaaaatctgcct 1226
97/22720, WO 97/43450, EP 0 799 897, EP 0 785 280, WO 97/31256, WO 97/27317, WO
98/08083 and Zhu and Snyder, 2001, Curr. Opin. Chem. Biol. 5: 40-45).
Microarrays comprising the nucleic acids may be applied e.g. in methods for analysing TTDA genotypes as indicated below. Microarrays comprising polypeptide may be used for detection of suitable candidates of TTDA mutants with altered affinities for binding partners or altered activities.
In another aspect the invention relates to method for analysing the NER status or genotype of a subject, a tissue sample or cell or cell-line, in particular its TTDA /
hTFBS genotype.
Analysing the NER status genotype is herein understood to mean analysing whether or not a 1 S genetic defect is present in the sample that underlies a defect in TFIIH
stability and/or levels, a defect in DNA transcription, a defect in NER in general and in particular a defect in the TCR
subpathway. The method preferably comprises the use of a nucleic acid molecule or probe or antibody as defined above. The method preferably is a method for diagnosing a TTD deficiency.
Alternatively, the method for diagnosing a DNA transcription deficiency or NER
/ TCR
deficiency is a method, which comprises the use of an antibody or antibody-fragment as defined above.
In another aspect the invention relates to an expression vector as defined above, wherein the vector is a vector that is suitable for gene therapy. Vectors that are suitable for gene therapy are described in Anderson 1998, Nature 392: 25-30; Walther and Stein, 2000, Drugs 60: 249-71;
Kay et al., 2001, Nat. Med. 7: 33-40; Russell, 2000, J. Gen. Virol. 81: 2573-604; Amado and Chen, 1999, Science 285: 674-6; Federico, 1999, Curr. Opin. Biotechno1.10: 448-53; Vigna and Naldini, 2000, .I. Gene Med. 2: 308-16; Marin et al., 1997, Mol. Med. Today 3:
396-403; Peng and Russell, 1999, Curr. Opin. Biotechnol. 10: 454-7; Sommerfelt, 1999, J.
Gen. Virol. 80: 3049-64; Reiser, 2000, Gene Ther. 7: 910-3; and references cited therein. The vectors are preferably formulated in a phamaceutical composition comprising a suitable pharmaceutical carrier as McC.'artln- Tetrault LLP TDO-RED #823651 D o. I
defined below. lVJethods for preparing administrable compositions are well known in the art and described in more detail in'various sources, including, for example, Remington: The Science and Practice of Pharmacy by Alfonso R. Gennaro, published by Lippincott Williams &
Wilkins; 20th edition, June 1, 2003.
S In a further aspect the invention relates to the use of a vector suitable for gene therapy as defined above in the manufacture of a medicament for the treatment of a NER, TCR of DNA
transcription deficiency, in particular a genetic defect in the TTDA gene.
Similarly the invention relates to a method for treating a TTDA genetic defect and/or a TFIIH
stabilizing deficiency, wherein the method comprising the step of administering to a subject suffering from a TTDA
deficiency, a pharmaceutical composition comprising a vector suitable for gene therapy as defined above, in an amount effective to overcome the deficiency.
The invention further relates to a pharmaceutical preparation comprising a polypeptide with TTDA stabilizing and NER, TCR and DNA transcription promoting activity as defined above. The composition preferably comprises a pharmaceutically acceptable carrier. In some methods, the polypeptide with TFIIH stabilizing activity purified from mammalian, insect or microbial cell cultures, from milk of transgeriic mammals or other source is administered in purified form together with a pharmaceutical carnet as a pharmaceutical composition. The preferred form depends on the intended mode of administration and therapeutic application. The pharmaceutical carrier can be any compatible, non-toxic substance suitable to deliver the polypeptides to the patient. Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions.
For oral administration, the active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. Active components) can be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like. Examples of additional inactive ingredients that may be added to provide desirable colour, taste, stability, buffering capacity, dispersion or other known desirable features are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, edible white ink and the rl~lc(~artlm Temcrul~ LLP TDO-RED #8236510 v. 1 like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain colouring and flavouring to increase patient acceptance. Methods for preparing administrable compositions are well known in the art and described in more detail in various sources, including, for example in Remington: The Science and Practice of Pharmacy by Alfonso R. Gennaro, published by Lippincott Williams & Wilkins; 20th edition, June 1, 2003.
Description of the figures Figure 1.
TTDA (hTFBS) is part of the TFIIH complex.
a. Immunoprecipitation (LP.) assays. Lane 1: molecular weight marker; lane 2-4: whole I S cell extracts (WCE) from MRCSSV (wt), TTD-A and TTD-A + p8; lane 5-6 LP.
from TTD-A and TTD-A + p8 cells extracts. Right panel: 18% SDS-PAGE gel on which are loaded 10 pg of proteins from WCE's and the a-p44 LP. cell extracts from TTD-A
and TTD-A + p8. The blot was immuno-stained with a -HA; the arrow shows the immuno-stained band corresponding to the HA-tagged p8. Middle and Left panel: 11% SDS-PAGE gels on which are loaded WCE and the a -HA LP. cell extracts from TTD-A
and TTD-A + p8. The blots were immuno-stained respectively with a-XPB and a -cdk7;
the arrows show the corresponding immuno-stained proteins.
b. The polypeptide p8 contained in the highly purified TFIIH from a HAP
column, co-purifies with the other nine identified components as shown at the top of the panel (silver staining of an 15% SDS-PAGE and immuno-blot) and with TFIIH transcription and repair activities. Lower panel: immuno-blotting identifies p8 in HAP
fractions. A rabbit polyclonal antibody raised against the C-terminal end of p8 was used for the detection of p8 in the HAP fractions containing TFIIH.
c. MALDI-MS identification of p8. Upper panel: P8 identification by MALDI
peptide mass fingerprinting. In the table the experimentally determined values as well as the ,McCarthv Tctrault LLP TDO-RED #823GS10 v. I
corresponding theoretical masses of p8 tryptic peptides are listed. Mass accuracy (ppM) and amino acidic sequences are also shown for each peptide. Middle panel:
Schematic representation of MALDI peptide fingerprinting results. P8 has been identified as CG14037 gene product in NCBI database Figure 2.
Correction of the DNA-repair deficiency of TTD-A by hTFBS.
a. Microneedle injection of an expression vector containing the wt cDNA of hTFBS (p8) in TTD99R0 (TTD-A) primary fibroblasts. Micrographs show the effect of p8 expression on DNA repair activity. Injected polynucleated primary fibroblasts (2), indicated by the arrow, exhibit a high (wild-type) level of UV-induced UDS, as apparent from the number of silver grains above their nuclei, when compared to the non-injected surrounding TTD-A fibroblasts (1), which express low residual UDS levels typical for TTD-A.
LTDS
correction by p8 microinjection was also observed when injected into the other TTD
group A cells, TTD1BR and TTD13PV (not shown).
b. Table summarizing the mutations found in the four cell lines analyzed derived from three unrelated TTD-A cases. In bold the mutated base in the codon.
Figure 3.
Nucleotide excision repair characteristics of TTDA.
a. UV-survival using wild-type MRCSSV (closed black diamonds), TTD1BRSV
(closed red triangles) and a cell population of TTD1BRSV expressing TTDA-HA (closed green squares). The percentage of surviving cells is plotted against the LTV-C dose, in J/mZ.
b. Locally UV-irradiated (40J/m2) TTDA-HA expressing TTD1BRSV are stained with a-HA (left panel) and a-XPB (right panel) antibodies. Locally damaged areas are indicated by the arrows.
c. TFIIH HAP fraction 6 (1 ~,1) was pre-incubated with either no antibody (lane 1), or increasing amounts of Ab-p8 (1, 5 and 10 pg; lanes 2-4 respectively), or Ab control (l, 5 and 10 fig; lanes 5-7 respectively) before being supplemented with all other NER factors;
McC anthy Turnuh LLI' TDO-RED #8236510 v. I
XPC-hR23b, XPA, RPA, XPG and ERCC1-XPF in addition to damaged DNA to measure dual incision.
Figure 4.
Recovery of reduced concentrations of TFIIH in TTD-A fibroblasts expressing TTDA-HA.
a. Mass population of TTD1BRSV expressing TTDA-HA. Cells expressing TTDA-HA
(left panel) show an increased level of XPB protein (right panel).
b. Mass population of TTD1BRSV expressing TTDA-HA. ERCC1 levels (right panel) are not influenced by TTDA-HA expression (left panel).
c. TTDA-HA expressing MRCSSV cells (left panel) show an increased level of XPB
protein (right panel).
Figure 5.
Primary amino acid sequence alignment of human TFBS with its homologs, showing conserved homology of hTFBS along evolutionary lines. Alignment. Displayed are TFBS
homologs in H.
Sapiens, M. musculus, A. thaliana, the C. elegans (all 71 aa), C. reinhardtii (78 aa), S. pombe (68 aa) and S. cerevisiae homolog (72 aa). Identical amino acids are in dark shaded boxes and physico-chemically related residues are in light shaded boxes.
A9c(-nrzht: Tezrnulz LLI' TDO-RED #8236510 n. l Examples Isolation and characterisation of cDNA and ~enomic clones encoding a human ortholo~ue of yeast TFBS.
Example 1 Cloning of hTFBS/TTDA
We cloned the human TFBS cDNA from primary fibroblasts by virtue of its homology with yeast TFBS using conventional techniques known in the art. An HA-tagged version of hTFBS (p8-HA) was constructed via conventional molecular cloning methods (Maniatis et al, supra) and expressed in TTD-A fibroblasts and subsequently used for immuno-precipitations with anti-HA (Figure 1 a). Both the XPB core TFIIH and the associated CAK
component (CDK7) were co-precipitated with p8-HA, in contrast to replication/repair factor RPAl (data not shown). Conversely, anti-p44 (another core-TFIIH component) co-precipitated p8-HA. We conclude that, analogous to yeast, this small polypeptide is associated with TFIIH in mammalian cells.
We further analyzed the association of p8 with TFIIH using - purified TFIIH
from HeLa cells (Gerard, M. et al., J. Biol. Chem. 266, 20940-20945, 1991). Silver-staining revealed that a protein-band of ~8 kDa co-purified with the other TFIIH subunits and with the transcription and DNA repair activities (Figure lb). MALDI peptide mass fingerprint analysis on tryptic digests of this ~ 8 kDa band showed that all identified peptides were part of hTFBS
(Figure 1 c). Finally, immuno-blotting using a polyclonal antibody raised against this 8 kDa polypeptide showed that it co-purifies with TFIIH (Figure 1B). These experiments unambiguously recognized this polypeptide as the human ortholog of TFBS and as a genuine, novel tenth component of TFIIH.
To confine that hTFBS is the gene affected in TTD-A, we microinjected the cDNA
into polynucleated TTD-A fibroblasts and determined the DNA repair capacity of injected cells by measuring UV-induced UDS (unscheduled DNA synthesis). Figure 2a shows a binucleated p8 injected cell (2) with a clearly increased UDS (elevated grain number) as compared to the low UDS in non-injected neighboring TTD-A cells (1). p8 cDNA corrected the repair defect of TTD-A cells to a comparable level as observed in wild-type cells assayed in parallel, indicating that hTFBS (p8) is affected in TTD group A.
JO
MeC'arthn Tetrnrrlt LLl' TDO-RED #82365/0 v.
ExamQle 2 TTDA diagnosis of subjects To verify that hTFB~ is implicated in TTD-A we analyzed genomic DNA of three unrelated TTD-A cases (Table 1 ). All three TTD-A patients showed an inactivating, although distinct, mutation within the hTFBS gene (Figure 2b). Patient TTD99R0 carnes a homozygous CST transition at codon 56, converting CGA (arginine) into a TGA stop codon, truncating the protein by 23%. Siblings TTD13PV and TTD14PV harbor (homozygously) a mutation in the start codon, converting ATG to ACG. This mutation will result in either a complete loss of protein synthesis or the production of an N-terminal truncated polypeptide (lacking the first and most conserved 15 amino acids (21%)), when a downstream AUG at codon 16 is used. Since only one allele was detected, both mutations can be considered functionally homozygous.
Finally, patient TTD1BR appeared a compound heterozygote: one allele being identical to TTD99R0 and the other carrying a TIC transition at codon 21, converting the conserved leucine residue to a proline. Genomic mutations were also identified in isolated mRNA, as revealed by RT-PCR, demonstrating that these alleles are expressed (data not shown). Together our data unambigously identified hTFBS as the NER-defect causing gene in TTD
group A. We designated this novel TFIIH subunit as TTDA (Accession nr. AJ634743).
The TTDA protein and DNA coding sequences provided in the sequence listing, SEQ ID
No 1 and SEQ ID No. 2 respectively, provide means to diagnose subjects for the presence of a gene defect in the TTDA gene. Detection of gene defects may be performed by various methods known in the art, in situ or in vitro on specimens from a subject such as but not limited to tissue samples, blood samples, hair samples, faeces, urine, saliva. Various techniques may be applied for mutation analysis of TTDA in a subject, such as but not limited to: DNA
sequencing of genomic DNA or cDNA, PCR or Nasba analysis, analysis using Southern blotting, expression analysis using northern or western blotting, DNA microarray or protein microarray analysis, SAGE analysis, EST or SNP analysis.
Example 3 TTDA involved in NER repair, an assay for TTDA activity To further explore the role of TTDA in NER we generated TTD1BR-SV cells stably expressing HA-tagged TTDA. Exposure of the TTDA-HA expressing cells to UV-C
light (Figure 3a) clearly showed that the cells exhibit a UV-sensitivity level comparable to NER
A~1~~C'arthr Tetrault LLP TDO-RED #823GS10 n. I
proficient cells assayed in parallel. Using an assay in which UV-damage is locally inflicted in cell nuclei by irradiation through a filter that contains (S pm) pores, we demonstrated previously that TFIIH components transiently accumulate at these sites (Mone, M.J. et al., EMBO Rep. 2, 1013-10117, 2001, Volker, M. et al., Mol. Cell 8, 213-224, 2001 and Hoogstraten, D. et al, Mol.
Cel. 10, 1163-1174, 2002). We applied the same procedure on TTDA-HA expressing cells to test participation of TTDA in the NER reaction in vivo. At local damaged sites, marked by the accumulation of endogenous XPB, TTDA-HA also accumulated (Figure 3b). This indicates that TTDA participates in the NER reaction similarly to other NER factors (Rademakers, S. et al., Mol. Cell. Biol. 23, 5755-5767, 2003).
We further developed an assay for testing the involvement of TTDA in NER in a reconstituted in vitro incision/excision repair assay, using recombinant NER
factors, purified TFIIH and a plasmid containing a cisplatin-adduct. Addition of increasing amounts of purified anti-TTDA (p8) polyclonal antibodies incubated with a fixed amount of purified TFIIH clearly inhibited the repair reaction, whereas treatment with pre-immune serum had no effect (Figure 1 S 3c). In conclusion, these results demonstrate that TTDA participates, as a part of TFIIH, in NER.
Moreover, a functional assay is here provided which allows testing of TTDA
protein preparations and TTDA proteins that are mutated or chemically or post translationally modified, for NER promoting activity. The reconstituted in vitro incision/excision repair assay described above (and as previously described in Shivji et al., 1999, Methods Mol. Biol, 113, 373-392) may be stripped / cleared from (endogenous) TTDA proteins using polyclonal or monoclonal antibodies using conventional techniques, for instance binding to immobilized secondary antibodies or immobilized protein A or protein G. Subsequently TTDA proteins, in particular variants forms thereof as described herein above, from various sources and preparations, chemically synthesized, in vitro translated preparations or purified TTDA from in vivo sources such as micro organisms, plants or animals, may be assayed for their NER
promoting activity in the in vitro repair reaction of the reconstitution assay.
A~lc(:artho Tctrnttlt LLP TDO-RED #b'23G510 0. !
Example 4 TFIIH stabilization assay The NER defect and TTD-specific features in TTD-A appeared to be linked to a reduced steady-state level of the total amount of TFIIH (Venneulen, W. et al., Nat.
Genet. 26, 307-13, 2000). As shown in Figure 4a, cells that express TTDA-HA have a concomitant higher XPB
level, suggesting that TTDA has a stabilizing function and protects TFIIH from degradation.
Similar observations were made in cells stairied with antibodies directed against other TFIIH
components, i.e. p62, p44 and CDK7, indicating that the intra-nuclear levels of the entire TFIIH
complex are increased. In contrast, non-TFIIH NER factors (ERCC 1 ) are not increased (Figure 4b). Additionally, in immunoblot experiments (Figure 1 a) elevated levels of XPB and CDK7 wexe also observed after TTDA expression.
These experiments show that the TFIIH concentration depends on the presence of the TTDA protein and hence provide a functional assay for TTDA protein activity.
The assay here provided allows functional testing of TTDA from various sources and preparations, TTDA
mutants, (both naturally occurring mutants and constructed mutants) and modified proteins. We transiently over-expressed TTDA-HA in MRCS (wild-type SV40-immortalized). Even in these TTDA-proficient cells transient over expression of the TTDA gene appeared to increase the cellular TFIIH content (Figure 4c), showing that TTDA expression regulates TFIIH
concentration in vivo. Overexpression of (functional) TTDA genes in TTDA-deficient cells enhances the relative TFIIH stabilization effect, whereas dysfunctional TTDA
mutants have a diminished effect or no effect, depending on the residual activity of the mutant.
One of the most obvious cellular phenotypes of cultured TTD-A cells is the severely reduced level (~ 30%) of TFIIH (Table 1). The fact that TTDA transiently increases the level of TFIIH even in wild-type cells (Figure 4c) demonstrates that this 8 kDa protein is involved in regulating steady-state levels of TFIIH. Because mRNA levels of TFIIH
components are not reduced in TTD-A cells (Vermeulen et al, 2000 supra), controlling the amounts of TFIIH by TTDA must be post-transcriptional. Regulation at the translational or post-translational level suggests a chaperone-like function of TTDA for complex-assembly or maintenance of the complex stn~cture. An altered tertiary structure of TFIIH, by the absence of TTDA, may impede Loth the longevity of this complex as well as its repair and transcription activity.
NcC artlro Tetrault LLI' TDO-RED #8236510 v. I
Although striking parallels on TFIIH composition, structure and functioning (Table 2) can be drawn between man and yeast, differences in TFBS's relative contribution to transcription efficiency are also observed. In yeast the absence of TFBS appeared to affect the efficiency of transcription and NER, whereas in man TTDA mutations affect transcription to some extent (Tirode, F., Busso, D., Coin, F. & Egly, J.M., Mol. Cell 3, 87-95, 1999).
Furthermore, in man the absence of TTDA appeared to predominantly affect TFIIH stability and or steady-state levels, whereas in yeast, absence of TFBS did not reduce TFIIH levels.
The severe effect on NER functioning suggests that NER requires higher concentrations of TFIIH than transcription. Recent live cell studies, showed that TFIIH
participates significantly longer in NER than in transcription (Hoogstraten, D. et al., Mol. Cel. 10, 1163-1174, 2002), providing a possible explanation for the increased need for sufficient amounts of TFIIH in NER.
Additionally, an altered structure of TFIIH by mutated TTDA may mainly affect the NER
function.
In conclusion, the identification of TTDA as a novel, evolutionarily conserved, tenth subunit of TFIIH provides essential information to understand the molecular mechanism of TFIIH function in DNA repair, transcription, and human disease. These findings unambiguously identify TTDA as the NER-defect causing gene in TTD group A, and provide an opportunity to diagnose and treat disorders caused by insufficient cellular levels of TFIIH, which may lead to deficiency in pol I and pol II DNA transcription, NER deficiency and in particular TCR
deficiency in a subject.
Methods and materials Cloning. For molecular cloning techniques general reference is made to Sambrook and Russell, 2001, Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY, and to Current Protocols in Molecular Biology, F.M. Ausubel ed., published by John Wiley & Sons Inc., December 2003. Nucleic acid modifying enzymes, hits, equipment and automated DNA synthesisers were used according to the manufacturer's 111StT'LlCt1011S.
McCcrrthv Tetnatrlt LLP TDO-RED #8?365/0 a. I
Cell lines, culture conditions and transfections. Primary human fibroblasts TTD99R0, TTD1BR, TTD13PV, TTD14PV (all TTD-A) and CSRO (wild type, NER-proficient) were cultured under standard conditions at 37°, 5% COz and 3% oxygen in Ham's F-10 medium (supplemented with 12% FCS and antibiotics (penicillin and streptomycin). SV-40 transformed cell lines TTD1BR-SV (TTD-A) and MRCS-SV (wild type) were cultured at 37°, 5% C02 in a 1:1 mixture of F-10 and DMEM (Gibco) supplemented with 8% FCS and antibiotics.
C-terminally HA-tagged TTDA was cloned into the expression vector pCDNA3 (Invitrogen), this construct was transfected into TTD1BRSV fibroblasts using FUGENE 6 transfection reagent (Roche).
Transfectants were submitted to triple ultraviolet-C irradiation of 8J1m2 with two-days intervals to enrich the population of TTDA-HA expressing cells. One week after the last irradiation stable transfectants were single cell sorted (FACSVantage, Becton Dickinson, Belgium). Single cell derived colonies were tested on the expression of the fusion gene by anti-HA
immunofluorescence. A
selected clone, stably expressing TTDA-HA was tested for its repair capacity (UV-survival, see below).
Immunoprecipitation and immunoblot analysis. Whole cell extracts from MRCSSV, TTD1BRSV and TTD1BRSV+hTFBSHA were prepared by isolating cells from 6 petri dishes per cell line (13 Cnl). Collected cell-pellets were washed once in PBS prior to lysis by Bouncing (20 strokes using a 12.61 mm Bounce homogenizer, Bellco Glass, INC., USA) in 2 ml of buffer A (SOmM Tris pH 7.9; 150 mM NaCI; 20% Glycerol; 0.1 % NP40; SmM (3-mercaptoethanol) supplemented with anti-proteases. Cellular extracts from MRCSSV, TTD1BRSV and TTD1BRSV+hTFBSHA were incubated overnight at 4°C in buffer A with respectively anti-HA
(12CA5) and anti-p44 (1H5) anti-bodies cross-linked to protein A-sepharose beads (Amersham Biosciences, UK). Prior to immuno-precipitations, cross-linked beads were washed 3 times in buffer A. After incubation with the extracts beads were extensively washed with buffer A, prior to analysis by SDS-PAGE and immunoblotting using anti-XPB (1B3), anti-cdk7 (2F8) and anti-HA (3F10).
Mass spectrometry.
McC.'artlr~: Tetrntrlt LLP TDO-RED #8236510 v, l TFIIH subunits were separated on a 15% polyacrylamide SDS-PAGE and silver stained (Rabilloud, T. Silver staining of 2-D electrophoresis gels. Methods Mol. Biol.
112, 297-305, 1999). The band migrating below the 10 kDa marker was excised and in gel-digested with trypsin (Cavusoglu, N., Brand, M., Tora, L. & Van Dorsselaer, Proteomics 3, 217-223, 2003).
Peptide extracts were speed-vac concentrated, chromatography purified on a C18 reverse-phase "ZipTip" pipette tip (Millipore) and finally eluted in 2 pl of acetonitrile 50%. 0.5 p,l of peptides were mixed either with an equal volume of saturated alpha-cyano-4 hydroxycinnamic acid (dissolved in 50% acetonitrile) or with a same volume of saturated 2,5-dihydroxybenzoic acid (dissolved in 20% acetonitrile). Both matrices were purchased from LaserBio Labs. Mass measurements were carried out on a Bruker Reflex IV MALDI-TOF spectrometer in the positive-ion reflector mode. The mass acquisition range was 800-3000 Da with a low mass gate set at 700 Da. Internal calibration was performed using autolytic trypsin peptides (MH+ with m/z = 842.51, 2211.11 and 2807.47). Mono-isotopic peptide masses were assigned manually using the Bruker X-TOF software. Database searches (NCBI, proteins of human origin), using parameters: MW between 0-10 kDa; trypsin digestion (one missed cleavage tolerated), cysteines modified by carbamidomethylation, methionine oxidation and mass tolerance of 75 ppM, were performed with the Profound program (ht~://prowl.rockefeller.edu/): 4 out of S
p8 peptides were detected in the MALDI spectrum using both alpha-cyano-4 hydroxycinnamic (data not shown) and 2,5-dihydroxybenzoic acids as matrix Microneedle injection and DNA repair assays. HTFBS cDNA constructs (with and without HA-tag) were microinjected into TTD-A fibroblasts (TTD99R0, TTD1BR) as described (Venneulen, W. et al,. Am J Hum. Genet. 54, 191-200, 1994). Briefly, 3 days prior to microinjection cells were fused using inactivated Sendai virus and seeded onto coverslips. 24 hrs after injection, to allow the expression of the injected gene, cells were exposed to 15 J/mZ
UV-C and incubated for 2 hr in culture medium supplemented with 3H-thymidine.
After removing the excess of free 3H-thymidine, cells were fixed. DNA repair capacity (UV-induced unscheduled DNA repair synthesis or UDS) was determined as the amount of autoradiographic grains above the nuclei, which is usually severely reduced in NER-deficient cells (for details see Venneulen, W. et al., Nat. Genet. 26, 307-13, 2000).
Nlc( ar7ho Tc%~raul~ LL P TDO-RED #8236510 ~:, l The sensitivity towards ultraviolet light of the TTD1BRSV (TTD-A) fibroblasts, TTD1BRSV+hTFBS-HA (TTD-A corrected) and the NER-proficient MRCSSV (wt) human fibroblasts was determined by 3H-thymidine incorporation, as described previously (Sijbers, A.M. et al., Nucleic Acids Res. 24, 3370-3380, 1996 and van Gool, A.J. et al., Embo J. 16, 5955-5965, 1997).
Mutation analysis on hTFBS gene and cDNA.
Total RNA (lOp.g) was extracted from wild type (CSRO) and TTDA primary fibroblasts (TTD99RO; TTD1 BR; TTD13PV and TTD14PV) using Rneasy Mini columns (Qiagen, USA) and used for preparation of cDNA by reverse transcription. Reverse transcription was performed using the Superscript tm First-Strand Synthesis System for RT-PCR (Invitrogen, USA).
Amplification of hTFBS cDNA was earned out using puReTaqTMReady-To-GoTMPCR
Beads (Amersham, USA) and 10 pmol of primers (Tm: 60°).
The coding region of the genomic hTFBS was amplified by using 2 sets of primers, covering the coding exons 2 and 3. Primers sequences are available on request.
Genomic DNA ( 100-500 ng) was amplified by using puReTaqTMReady-To-GoTMPCR
beads (Amersham, USA) and 10 pmol of each primer set. Amplification products were cloned into T-easy vector (Promega, USA). For each cell line 18 independent clones were sequenced by BaseClear labservices (BaseClear, The Netherlands).
Immunofluorescence. Two days after micro-needle injection or transfection, cells were washed twice in PBS and then fixed in 2% parafonnaldehyde and permeabilized by 2 times 10 minutes rinsing in PBS containing 0.1 % Triton X-100 (PBS-T), followed by washing with PBS+ (PBS+
0.15% glycine and 0.5% BSA). Antibodies, diluted in PBS+ were incubated for 2 h. at RT in a moist chamber, dilutions are: anti-XPB (IB3), 1000x; anti-HA (3F10, Roche), 1000x.
Subsequently, coverslips were washed (Sx; 5 min) in PBS-T, and incubated with the secondary antibody, respectively: goat anti-mouse, Cy3-conjugated (The Jackson Laboratory); goat anti-rat, Alexa 488-conjugated (Molecular Probes), each diluted 1000x in PBS+. After the same washing procedure, coverslips were mounted in Vectashield mounting medium (Vector Laboratories) McCarthv Tetrault L LP TDO-RED #8236510 n. l containing DAPI~(4'-6-diamino-2-phenylindole) at 1.5 pglp,l. Epifluorescent and phase-contrast images were produced on a Leitz Aristoplan microscope equipped with epi-fluorescence optics and a PLANAPO 63x/'1.40 oil immersion lens.
Dual incision NER assay. Dual incision assay was carried out as described previously (Riedl, T., Hanaoka, F. & Egly, J.M., Embo J. 22, 5293-5303, 2003)., in 25 p.l dual incision buffer supplemented with 2mM ATP. Each reaction contained 5ng of XPG, l5ng of XPF/ERCC1, l Ong of XPC-hHR23B, 50rtg of RPA, 25ng of XP~A and TFIIH as indicated. ~
Following 10 min of pre-incubation at 30 °C, 30ng of Pt DNA is added and the reactions are continued for 90 min at 30°C. The excised fragment is detected on 14 % urea-acrylamide after annealing with 9ng of the complementary oligonucleotide and addition of four radio labeled dCMPoc-P3a (3000pCi/mmol) residues by Sequenase V2.1 (USB). Prior to the addition to the repair reactions, TFIIH was preincubated with either p8 polyclonal anti-bodies or pre-immune serum.
The rabbit polyclonal was produced by coupling the peptide VGELMDQNAFSLTQK (57-71) to ovalbumin and injecting it in rabbit.
Local Ultraviolet Irradiation. Cultured cells were UV-irradiated (254 nm) at 40J/m2 through an isopore polycarbonate,filter (Millipore) containing pores of 5 ~m in diameter as described previously (hone, M.J. et al., EMBO Rep. 2, 1013-10117, 2001 and Volker, M. et al., Mol. Cell 8, 213-224, 2001 ). Subsequently, after filter removal cells were fixed with paraformaldheyde and further processed for immuno-cytochemistry as described above.
Accession numbers. The complete human TTDA cDNA sequence is available under BC060317, AK055106 or AJ634743. The human genomic TTDA sequence may be found in the human chromosome 6q25.3 contig, which is available under Hs 356224 and NT-007422, chr. 6 contig Hs_7579.
A4c(-nrtln. Tetrauh i_LP TDO-RED #8236 l0 v. I
nook ~ ~ ~ ~
o o ~ ., ., .
~.c ~z x ~ c~ G x a ~ ~ o o ~ a a ' ~ ~ ' ~ =.
<
-~ o ~ c w C
~ ~ "' ~ n " b c 0 'x ~ ~ ~ z~ ~ g ~ ~ 9 y '' ~~ ~'~~ '~ ~ x ~ ~ n c ~ " ~ ~~ ~
o ~
u ~ ei ...
I o ' ~ ~ b b m G
m " . .
n ~ o ! b . o ' b m m o ~
-. a ~ ~~g ~ ~ ~
~,~b ~ c ~
a ~. -T
w c~
v .
C ~ p ~ N ~ + I I I (]
. +
v a ~ ~ ~, ~ ' a ~ a ar n o~
- a -n o ..i~ o + p I ~ ~ >C ~! n ~
v ~ o ' ~ ~ ci a ~ v Q N o ~ o o '- ~' C : 7C n m C O x c~ b N
CD ~ o d ~
~
b w ~. o + c~ + I ~ yC ~7 -v f ~' ' Q 'v~~O ~ O _ yC
CD a X
~
~ Cn w ~ ~
N o z ~ ' ~ ~ ~. < b b n w'. o m-~ o b , ~ a ~ v 0 o d x Q
il' d x F $
m o ~
~
Q ~ z o ~ sy + ~ 3 ~
U ~ ~ H
o ~ n t x c.: . C7 p n n a a ', a -a a ~' co O n N l N p ~, n +
~
o w J _' a. -, ~ d t o ~ ~
~ O :
~
, . n .
Q
w o ~ fy + I ~
~
II o ~ F c.: n, d d p ~
~
v Q 0 9 w O ''' (D ,...
. ~
cn <
a c am Table 2 TFIIH subunits in mammals and yeast:
predicted % identity subunitMammalian S.CerevisiaeProtein Properties between size human in kDa yeast (human) 1 XPB RAD25/SSL2 89 Helicase, 49 5'-3' 2 XPD RAD3 80 Helicase, 51 3'-5 3 GTF2H1 (hTFB1) TFB1 62 21 4 GTF2H2 SSL1 44 Zn-finger 34 GTF2H3 (hTFB4) TFB4 34 Ring-finger 29 6 GTF2H4 (hTFB2) TFB2 52 34 7 MAT1 (hTFB3) TFB3 32 Ring-finger 31 8 CDK7 KIN28 41 CTD kinase 41 9 Cyclin H CCL1 38 cyclin motifs23 GTF2H5 (hTFBS TFBS* 28 10* l 8 TTDA) Mc( crrtho Tetrault LLP TDO-RED #8?365/0 v. l SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: Universitair Medisch Centrum Rotterdam (ii) TITLE: NOVEL TFIIH SUBUNIT
(iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS:
FILE REFERENCE: T00590-0371-CA
(v) COMPUTER READABLE FORM:
(D) SOFTWARE:
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,471,063 (B) FILING DATE: JULY 6, 2004 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: NONE
(B) FILING DATE: NONE
(2) INFORMATION FOR SEQ. ID NO: l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 71 (B) TYPE: PRT
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (iii) FEATURE:
(A) NAME/KEY: unknown (B) LOCATION: unknown (iv) SEQUENCE DESCRIPTION: SEQ. ID NO: 1:
Met Val Asn Val Leu Lys Gly Val Leu Ile Glu Cys Asp Pro Ala Met Lys Gln Phe Leu Leu Tyr Leu Asp Glu Ser Asn Ala Leu Gly Lys Lys Phe Ile Ile Gln Asp Ile Asp Asp Thr His Val Phe Val Ile Ala Glu Leu Va1 Asn Val Leu Gln Glu Arg Val Gly Glu Leu Met Asp Gln Asn Ala Phe Ser Leu Thr Gln Lys (2) INFORMATION FOR SEQ. ID N0: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 331 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo Sapiens (iii) FEATURE:
(A) NAME/KEY: unknown (B) LOCATION: unknown (iv) SEQUENCE DESCRIPTION: SEQ. ID N0: 2:
ggcgcttctg catctgtggg ccgagcattc ttcaggtcat ctgaaccttc tgagaaaaca 60 tggtcaacgt cttgaaagga gtgcttatag aatgtgatcc tgccatgaag cagtttctgc 120 tgtacttgga tgagtccaat gccctgggga agaagttcat cattcaagac attgatgaca 180 ctcacgtctt tgtaatagca gaattggtta atgtcctcca ggagcgagtg ggtgaattaa 240 tggaccaaaa tgctttttcc cttacccaga aatgaaaata ctcaatatgg accatttagg 300 aattataagc agcaactgtg aaagacttgc c 331 (2) INFORMATION FOR SEQ. ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 89 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (iii) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: unknown (C) OTHER INFORMATION: exon l, non coding, nucl. 22 - 65 (iv) SEQUENCE DESCRIPTION: SEQ. ID NO: 3:
gatggcgtat cggcgaggcg cactctgccg gcaacgccga ggcgcttctg catctgtggg 60 ccgaggtgtg tggcgagcgt ccgagcggc 89 (2) INFORMATION FOR SEQ. ID N0: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo Sapiens (iii) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: unknown (C) OTHER INFORMATION: exon 2 ranges from nucl. 19 to 89 CDS starts at nucl. 55, ATG.
(iv) SEQUENCE DESCRIPTION: SEQ. ID N0: 4:
taccttactc tttttattag cattcttcag gtcatctgaa ccttctgaga aaacatggtc 60 aacgtcttga aaggagtgct tatagaatgg ttagtagttt tgatactgca 110 (2) INFORMATION FOR SEQ. ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1226 (B) TYPE: DNA
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens (iii) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: unknown (C) OTHER INFORMATION: exon 3 ranges from nucl. 27 to 1226 CDS ends at nucl. 206, TGA stopcodon (iv) SEQUENCE DESCRIPTION: SEQ. ID N0: 5:
cttacaatca tgtgtttgtc tttacagtga tcctgccatg aagcagtttc tgctgtactt 60 ggatgagtcc aatgccctgg ggaagaagtt catcattcaa gacattgatg acactcacgt 120 ctttgtaata gcagaattgg ttaatgtcct ccaggagcga gtgggtgaat taatggacca 180 aaatgctttt tcccttaccc agaaatgaaa atactcaata tggaccattt aggaattata 240 agcagcaactgtgaaagacttgccactcaatatcttaggtgactgattagacatagaggg300 ttgttttaggagcatgccacgggaaagactgagggatcatgatcatttgttcagaaaaaa360 agcccctgaactgattttgttaccatagaatttaaaaaaaaaaaaagctttaacagttgg420 ctgtaatttggcttttattatcctttattaaaatacaaatgtcaatgcttttcctgcctt480 tttaataccatgtcagtgtaacataggtatttattttgctcatccctgtgatctgtgcat540 ttttgctgcgtggatgtgattgtttggtttcagttagaaacgtcatagatttgctgtttg600 aatatgccaaggtggggacttagacattatgtacgtctcacaaatcctacctgcatacca660 gtcagctctattgaggaagacaatgtaaaactaatgtaaactacagtttgcatttccctg720 aaaacagaatattgtttttaagagggttagaaacaaccagtgggaaaggcacatgctgct780 ttgtttagtttttccttgttcaaactttgttggtcacattttcccatctgtattcttttt840 tattaagaaaacagcttagggaggctgaggtgggaggattgcttgagcccaggagtccga900 ggttgctacaaaaacaccattgcactctggcctggacaacagagagaccctgcctcaaaa960 aaaaaaaaaaaaaaaaaaaaaattctacttgtaccttattccctatgagaatacttatca1020 aacttatctaaaaaagaaaaataggaacagccatatgcaaagtcagcccaacaggaaagg1080 acatattagattaaaatacattgcggcctgggcttagtggctcacacctgtaatcccagc1140 actttgggaggctgaggcaggcagatcgcttgagtccaggagtcgaaaccctgtctctac1200 aaaaaaaaaaatacaaaaatctgcct 1226
Claims (29)
1. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide capable of interacting with TFIIH, wherein the nucleotide sequence is selected from:
a) a nucleotide sequence encoding a polypeptide having an amino acids sequence that has at least 50% amino acid sequence identity with SEQ ID No 1;
b) a nucleotide sequence that has at least 50% nucleotide sequence identity with SEQ ID No 2 or 3;
c) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (a) or (b); and, d) a nucleotide sequence which differs from the nucleotide sequence of (c) due to the degeneracy of the genetic code.
a) a nucleotide sequence encoding a polypeptide having an amino acids sequence that has at least 50% amino acid sequence identity with SEQ ID No 1;
b) a nucleotide sequence that has at least 50% nucleotide sequence identity with SEQ ID No 2 or 3;
c) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (a) or (b); and, d) a nucleotide sequence which differs from the nucleotide sequence of (c) due to the degeneracy of the genetic code.
2. A nucleic acid according to claim 1, wherein the polypeptide has TFIIH
stabilizing activity.
stabilizing activity.
3. A nucleic acid according to claim 1 or 2, wherein the polypeptide has NER
promoting activity.
promoting activity.
4. A nucleic acid according to any of the preceding claims, wherein the nucleotide sequence encodes a mammalian TFIIH 8 kDa subunit TTDA.
5. A nucleic acid according to any of the preceding claims, wherein the nucleotide sequence encodes a human or a murine TTDA or a derivative thereof.
6. A nucleic acid probe, wherein the probe comprises at least 10 contiguous nucleotides of a nucleotide sequence that has at least 90% identity with a nucleotide sequence as depicted in SEQ
ID No. 2.
ID No. 2.
7. The nucleic acid probe according to claim 6 immobilized on a solid support.
8. A vector comprising a nucleic acid molecule or probe as defined in any one of claims 1 - 7.
9. An expression vector comprising a nucleic acid molecule according to any one of claims 1 -7, wherein the nucleotide sequence encoding the polypeptide is operably linked to a promoter capable of directing expression of the coding sequence in host cells for the vector.
10. The expression vector according to claim 9 wherein the nucleotide sequence encoding the polypeptide comprises a second nucleotide sequence encoding a molecular tag, whereby the second coding sequence is fused in frame to the sequence encoding the polypeptide.
11. The expression vector according to claim 10, wherein the molecular tag is a fluorescent tag or an affinity tag.
12. A host cell comprising a vector according to any one of claims 8 - 11.
13. A method for producing a polypeptide with TFIIH interacting or stabilizing activity, the method comprising the step of culturing a host cell as defined in claim 12 under conditions conducive to the expression of the polypeptide, and, optionally recovering the polypeptide.
14. A transgenic animal comprising in its somatic and germ cells a vector according to claims 8 to 11.
15. The transgenic animal according to claim 14 wherein the vector is integrated via homologous recombination in the endogenous TTDA locus.
16. The transgenic animal according claims 14 or 15 wherein the nucleotide sequence encoding the polypeptide comprises a mutation.
17. The transgenic animal according to claim 16 wherein the mutation is an inactivating mutation.
18. A polypeptide with TFIIH interacting activity and comprising an amino acid sequence having at least 50% identity with the amino acid sequence of SEQ ID No. 1.
19. A polypeptide according to claim 18, wherein the polypeptide has TFIIH
stabilizing activity.
stabilizing activity.
20. A polypeptide according to claim 18, wherein the polypeptide has NER
promoting activity.
promoting activity.
21. An antibody or antibody-fragment that specifically binds to a polypeptide as defined in any one of claims 18 - 20.
22. A method for analysing the TTDA genotype of a subject, the method comprising the use of a nucleic acid molecule or probe as defined in any one of claims 1 - 7.
23. A method according to claim 22, wherein the method is a method for diagnosing an NER
deficiency.
deficiency.
24. A method for diagnosing an NER deficiency, wherein the method comprises the use of an antibody or antibody-fragment as defined in claim 21.
25. An expression vector according to claims 8 - 11, wherein the vector is a vector that is suitable for gene therapy.
26. A pharmaceutical preparation comprising a vector as defined in claim 25.
27. Use of a vector as defined in claim 25 or a nucleic acid molecule as defined in claims 1 - 7, as a medicament.
28. Use of a vector as defined in claim 25 or a nucleic acid molecule as defined in claims 1 - 7, for the manufacture of a medicament for the treatment of a UV sensitivity syndrome or a NER
deficiency.
deficiency.
29. A method for treating a UV sensitivity disorder in a subject, comprising administering a source of a polypeptide as defined in any one of claims 18 - 20.
29. The method according to claim 28 wherein the source of the polypeptide is a vector as defined in claim 25 or a nucleic acid molecule as defined in claims 1 - 7.
29. The method according to claim 28 wherein the source of the polypeptide is a vector as defined in claim 25 or a nucleic acid molecule as defined in claims 1 - 7.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2471063 CA2471063A1 (en) | 2004-07-06 | 2004-07-06 | Novel tfiih subunit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2471063 CA2471063A1 (en) | 2004-07-06 | 2004-07-06 | Novel tfiih subunit |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2471063A1 true CA2471063A1 (en) | 2006-01-06 |
Family
ID=35589171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2471063 Abandoned CA2471063A1 (en) | 2004-07-06 | 2004-07-06 | Novel tfiih subunit |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2471063A1 (en) |
-
2004
- 2004-07-06 CA CA 2471063 patent/CA2471063A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cantor et al. | BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function | |
Satoh et al. | Differential sublocalization of the dynamin-related protein OPA1 isoforms in mitochondria | |
Solari et al. | The Caenorhabditis elegans genes egl-27 and egr-1 are similar to MTA1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning | |
Vogt et al. | ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth | |
US8999660B2 (en) | Methods Relating to Mammalian Rictor Polypeptide | |
Zhang et al. | Evidence that dim1 associates with proteins involved in pre-mRNA splicing, and delineation of residues essential for dim1 interactions with hnRNP F and Npw38/PQBP-1 | |
US20090077679A1 (en) | Gene silencing by systemic rna interference | |
Ishikawa et al. | Identification of DRG family regulatory proteins (DFRPs): specific regulation of DRG1 and DRG2 | |
Kelly et al. | Specific functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia | |
Belfiore et al. | Roles of the C. elegans cyclophilin-like protein MOG-6 in MEP-1 binding and germline fates | |
Keppner et al. | Androglobin, a chimeric mammalian globin, is required for male fertility | |
JP2004500807A (en) | Screening method for candidate drugs | |
Ghersi et al. | The intracellular localization of amyloid β protein precursor (AβPP) intracellular domain associated protein-1 (AIDA-1) is regulated by AβPP and alternative splicing | |
Inoue et al. | ELKS, a protein structurally related to the active zone protein CAST, is involved in Ca2+‐dependent exocytosis from PC12 cells | |
EP1516930A1 (en) | Cellular model of tauopathies for lead identification and drug discovery | |
Liu et al. | Cilium proteomics reveals Numb as a positive regulator of the Hedgehog signaling pathway | |
US20060008875A1 (en) | Novel TFIIH subunit | |
Jang et al. | GJA1 depletion causes ciliary defects by affecting Rab11 trafficking to the ciliary base | |
Johnston et al. | Harp (harmonin‐interacting, ankyrin repeat‐containing protein), a novel protein that interacts with harmonin in epithelial tissues | |
CA2471063A1 (en) | Novel tfiih subunit | |
EP1858922A2 (en) | A novel component of the wg/wnt signaling pathway | |
US20070071755A1 (en) | Novel nucleolar GTPases and method for controlling proliferation of cells | |
AU2004203009A1 (en) | Novel TFIIH Subunit | |
CA3076371C (en) | Non-human animals comprising slc30a8 mutation and methods of use | |
US7125976B2 (en) | Method of screening for agents inhibiting chloride intracellular channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |